

SEQUENCE LISTING

<110> LIU, CHUAN-FA
FEIGE, ULRICH
CHEETHAM, JANET
BOONE, THOMAS CHARLES

<120> MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

<130> A-527

<140> NOT YET RECEIVED

<141> 1999-10-22

<150> 60/105,371

<151> 1998-10-23

<160> 1133

<170> PatentIn Ver. 2.1

<210> 1

<211> 684

<212> DNA

<213> HUMAN

<220>

<221> CDS

<222> (1)..(684)

<400> 1

atg gac aaa act cac aca tgt cca cct tgt cca ggc ccg gaa ctc ctg 48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc 96
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc 144
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag 192
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg 240

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr		
65					70					75					80		
tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	288	
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn		
				85					90					95			
ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	336	
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro		
			100					105					110				
atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	384	
Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln		
			115				120					125					
gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	432	
Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val		
			130				135					140					
agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	480	
Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val		
145					150					155					160		
gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	528	
Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro		
				165				170					175				
ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	576	
Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr		
				180				185					190				
gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	624	
Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val		
			195				200					205					
atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	672	
Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu		
			210			215					220						
tct	ccg	ggt	aaa													684	
Ser	Pro	Gly	Lys														
225																	

<210> 2
 <211> 228
 <212> PRT
 <213> HUMAN

<400> 2
 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15
 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30
 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45
 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60
 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80
 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95
 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220
 Ser Pro Gly Lys
 225

<210> 3
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PEGYLATED
PEPTIDE

<400> 3
Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
1 5 10 15

Arg Ala

<210> 4
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PEGYLATED
PEPTIDE

<400> 4
Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
1 5 10 15

Arg Ala

<210> 5
<211> 794
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-TMP

<220>
<221> CDS
<222> (39)..(779)

<400> 5

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56

Met Asp Lys Thr His Thr

1

5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
105 110 115

aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
120 125 130

tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
135 140 145 150

aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
155 160 165

cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp

170

175

180

ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632
 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
 185 190 195

cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680
 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 200 205 210

aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728
 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly
 215 220 225 230

ggg ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 776
 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 235 240 245

gct taatctcgag gatcc 794
 Ala

<210> 6

<211> 247

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TMP

<400> 6

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

100	105	110
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln		
115	120	125
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val		
130	135	140
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val		
145	150	155
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
165	170	175
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr		
180	185	190
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val		
195	200	205
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
210	215	220
Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg		
225	230	235
Gln Trp Leu Ala Ala Arg Ala		
245		

<210> 7
 <211> 861
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Fc-TMP-TMP

<220>
 <221> CDS
 <222> (39)..(842)

<400> 7
 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
 Met Asp Lys Thr His Thr
 1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc	104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe	
10 15 20	
ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct	152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro	
25 30 35	
gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc	200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val	
40 45 50	
aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca	248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr	
55 60 65 70	
aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc	296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val	
75 80 85	
ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys	
90 95 100	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser	
105 110 115	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca	440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro	
120 125 130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val	
135 140 145 150	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly	
155 160 165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp	
170 175 180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp	
185 190 195	

cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680
 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 200 205 210

aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728
 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly
 215 220 225 230

ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 776
 Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 235 240 245

gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca acc ctt cgc 824
 Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 250 255 260

caa tgg ctt gca gca cgc gcataatctc gaggatccg 861
 Gln Trp Leu Ala Ala Arg
 265

<210> 8

<211> 268

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TMP-TMP

<400> 8

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 225 230 235 240

Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile
 245 250 255

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 260 265

<210> 9

<211> 855

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TMP-TMP-Fc

<220>

<221> CDS

<222> (39)..(845)

<400> 9

tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56
 Met Ile Glu Gly Pro Thr

1

5

ctg cgt cag tgg ctg gct gct cgt gct ggc ggt ggt ggc gga ggg ggt	104
Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly	
10 15 20	
ggc att gag ggc cca acc ctt cgc caa tgg ctt gca gca cgc gca ggg	152
Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly	
25 30 35	
gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca gca cct	200
Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	
40 45 50	
gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag	248
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	
55 60 65 70	
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg	296
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	
75 80 85	
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac	344
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	
90 95 100	
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac	392
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	
105 110 115	
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac	440
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	
120 125 130	
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc	488
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	
135 140 145 150	
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga	536
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	
155 160 165	
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag	584
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys	
170 175 180	
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac	632
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	

185	190	195	
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag			680
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys			
200	205	210	
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc			728
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser			
215	220	225	230
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca			776
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser			
235	240	245	
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc			824
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser			
250	255	260	
ctc tcc ctg tct ccg ggt aaa taatggatcc			855
Leu Ser Leu Ser Pro Gly Lys			
265			
<210> 10			
<211> 269			
<212> PRT			
<213> Artificial Sequence			
<223> Description of Artificial Sequence:TMP-TMP-Fc			
<400> 10			
Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly			
1 5 10 15			
Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp			
20 25 30			
Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys			
35 40 45			
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu			
50 55 60			
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu			
65 70 75 80			
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys			
85 90 95			

Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys
				100				105					110		
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu
		115					120					125			
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys
		130				135					140				
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys
145					150					155					160
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser
				165					170						175
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys
			180					185					190		
Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln
		195					200					205			
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly
	210					215					220				
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln
225					230					235					240
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn
				245					250					255	
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys			
			260					265							

<210> 11

<211> 789

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TMP-Fc

<220>

<221> CDS

<222> (39)..(779)

<400> 11

tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56

Met Ile Glu Gly Pro Thr

1

5

ctg cgt cag tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa 104
Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys

10

15

20

act cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg 152
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro

25

30

35

tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc 200
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser

40

45

50

cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac 248
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp

55

60

65

70

cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat 296
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn

75

80

85

gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg 344
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val

90

95

100

gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag 392
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu

105

110

115

tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa 440
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys

120

125

130

acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc 488
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr

135

140

145

150

ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc 536
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr

155

160

165

tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag 584
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu

170

175

180

agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg 632
 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
 185 190 195

gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag 680
 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
 200 205 210

agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag 728
 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
 215 220 225 230

gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt 776
 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 235 240 245

aaa taatggatcc 789
 Lys

<210> 12

<211> 247

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:TMP-Fc

<400> 12

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 1 5 10 15

Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 20 25 30

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 35 40 45

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 50 55 60

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 65 70 75 80

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 85 90 95

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 100 105 110

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 115 120 125

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 130 135 140

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
 145 150 155 160

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 165 170 175

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 180 185 190

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 195 200 205

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 210 215 220

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 225 230 235 240

Leu Ser Leu Ser Pro Gly Lys
 245

<210> 13

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TMP

<400> 13

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 14

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TMP-TMP

<400> 14

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 15

<211> 812

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP

<220>

<221> CDS

<222> (39)..(797)

<400> 15

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc	296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val	
75 80 85	
ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys	
90 95 100	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser	
105 110 115	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca	440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro	
120 125 130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val	
135 140 145 150	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly	
155 160 165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp	
170 175 180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp	
185 190 195	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac	680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His	
200 205 210	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga	728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly	
215 220 225 230	
ggg ggt ggt gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg	776
Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp	
235 240 245	
gtt tgc aaa ccg cag ggt ggt taatctcgtg gatcc	812
Val Cys Lys Pro Gln Gly Gly	
250	

<210> 16
 <211> 253
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:Fc-EMP

<400> 16

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
1				5					10					15	

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
			20					25					30		

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
		35					40					45			

His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
	50					55					60				

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
65					70					75					80

Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
				85					90					95	

Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro
			100					105					110		

Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln
		115					120					125			

Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val
	130					135					140				

Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val
145					150					155					160

Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro
				165					170					175	

Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr
			180					185					190		

Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val
		195					200					205			

Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

210 215 220
 Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
 245 250

<210> 17
 <211> 807
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EMP-Fc

<220>
 <221> CDS
 <222> (39)..(797)

<400> 17
 tctagatttg ttttaactaa ttaaaggagg aataacat atg gga ggt act tac tct 56
 Met Gly Gly Thr Tyr Ser
 1 5

tgc cac ttc ggc ccg ctg act tgg gta tgt aag cca caa ggg ggt ggg 104
 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 10 15 20

gga ggc ggg ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 152
 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 25 30 35

gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 200
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 40 45 50

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 248
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 55 60 65 70

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 296
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 75 80 85

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 344

Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr				
90								95				100							
aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	392			
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp				
105								110				115							
tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	440			
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu				
120								125				130							
cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	488			
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg				
135								140				145				150			
gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	536			
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys				
				155								160				165			
aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	584			
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp				
				170								175				180			
atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	632			
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys				
185								190								195			
acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	680			
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser				
200								205								210			
aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	728			
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser				
215								220								225		230	
tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	776			
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser				
				235								240				245			
ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc									807			
Leu	Ser	Leu	Ser	Pro	Gly	Lys													
250																			

<210> 18
 <211> 253
 <212> PRT
 <213> Artificial Sequence

<223> Description of Artificial Sequence:EMP-Fc

<400> 18

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
20 25 30

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
35 40 45

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
50 55 60

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
65 70 75 80

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
85 90 95

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
100 105 110

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
115 120 125

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
130 135 140

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
145 150 155 160

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
165 170 175

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
210 215 220

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
225 230 235 240

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 19
 <211> 881
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EMP-EMP-Fc

<220>
 <221> CDS
 <222> (41)..(871)

<400> 19
 tctagatttg agttttaact tttagaagga ggaataaaat atg gga ggt act tac 55
 Met Gly Gly Thr Tyr
 1 5
 tct tgc cac ttc ggc cca ctg act tgg gtt tgc aaa ccg cag ggt ggc 103
 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
 10 15 20
 ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat ttt ggc ccg ctg acc 151
 Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
 25 30 35
 tgg gta tgt aag cca caa ggg ggt ggg gga ggc ggg ggg gac aaa act 199
 Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr
 40 45 50
 cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca 247
 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 55 60 65
 gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 295
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 70 75 80 85
 acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct 343
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 90 95 100
 gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc 391
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

105	110	115	
aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc			439
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val			
120	125	130	
agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac			487
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr			
135	140	145	
aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc			535
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr			
150	155	160	165
atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg			583
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu			
170	175	180	
ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc			631
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys			
185	190	195	
ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc			679
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser			
200	205	210	
aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac			727
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp			
215	220	225	
tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc			775
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser			
230	235	240	245
agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct			823
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala			
250	255	260	
ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa			871
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys			
265	270	275	
taatgatcc			881

<210> 20
 <211> 277
 <212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:EMP-EMP-Fc

<400> 20

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20 25 30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35 40 45

Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
50 55 60

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
65 70 75 80

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
85 90 95

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
100 105 110

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
115 120 125

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
130 135 140

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
145 150 155 160

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
165 170 175

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
180 185 190

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
195 200 205

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
210 215 220

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
225 230 235 240

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
245 250 255

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
260 265 270

Leu Ser Pro Gly Lys
275

<210> 21
<211> 884
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-EMP-EMP

<220>
<221> CDS
<222> (39)..(869)

<400> 21
tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys	
90 95 100	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser	
105 110 115	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg cct cca	440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro	
120 125 130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val	
135 140 145 150	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly	
155 160 165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp	
170 175 180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp	
185 190 195	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac	680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His	
200 205 210	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga	728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly	
215 220 225 230	
ggt ggt ggc gga ggt act tac tct tgc cac ttc ggc cca ctg act tgg	776
Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp	
235 240 245	
gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc	824
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser	
250 255 260	
tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt	869
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly	
265 270 275	

taatctcgag gatcc

884

<210> 22

<211> 277

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-EMP-EMP

<400> 22

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
1				5					10					15	

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
			20					25					30		

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
		35					40						45		

His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
	50					55					60				

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
65					70					75					80

Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
				85					90					95	

Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro
			100					105					110		

Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln
		115					120					125			

Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val
	130					135					140				

Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val
145					150					155				160	

Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro
				165					170					175	

Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr
			180					185					190		

Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

195

200

205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
245 250 255

Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
260 265 270

Lys Pro Gln Gly Gly
275

<210> 23

<211> 1545

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:pAMG216

<400> 23

cgtaacgtat gcatggtctc cccatgcgag agtaggggaac tgccaggcat caaataaaaac 60
gaaaggctca gtcgaaagac tgggcctttc gttttatctg ttgtttgtcg gtgaacgctc 120
tcctgagtag gacaaatccg ccgggagcgg atttgaacgt tgcgaagcaa cggcccggag 180
ggtggcgggc aggacgcccg ccataaactg ccaggcatca aattaagcag aaggccatcc 240
tgacggatgg cctttttgcg tttctacaaa ctcttttgtt tatttttcta aatacattca 300
aatatggacg tcgtacttaa ctttttaaagt atgggcaatc aattgctcct gttaaaattg 360
ctttagaaat actttggcag cggtttgttg tattgagttt catttgcgca ttggttaaatt 420
ggaaagtgc cgtgcgctta ctacagccta atatttttga aatatcccaa gagctttttc 480
cttcgcatgc ccacgctaaa cattcttttt ctcttttggg taaatcggtg tttgatttat 540
tatttgctat atttattttt cgataattat caactagaga aggaacaatt aatggtatgt 600
tcatacacgc atgtaaaaat aaactatcta tatagttgtc tttctctgaa tgtgcaaaaac 660
taagcattcc gaagccatta ttagcagtat gaataggga actaaaccca gtgataagac 720
ctgatgattt cgcttcttta attacatttg gagatttttt atttacagca ttgttttcaa 780
atatattcca ataatcggg gaatgattgg agttagaata atctactata ggatcatatt 840
ttattaaatt agcgtcatca taatattgcc tccatttttt agggtaatta tccagaattg 900
aaatatcaga ttttaaccata gaatgaggat aatgatcgc gagtaaataa tattcacaat 960
gtaccatttt agtcatatca gataagcatt gattaatatc attattgctt ctacaggctt 1020
taatttttatt aattattctg taagtgtcgt cggcatttat gtctttcata cccatctctt 1080
tattcttacc tattgtttgt cgcaagtttt gcggtgttata tatcattaaa acggtaatag 1140
attgacattt gattctaata aattggattt ttgtcacact attatatcgc ttgaaataca 1200

attgtttaac ataagtacct gtaggatcgt acagggtttac gcaagaaaat ggtttggttat 1260
 agtcgattaa tcgatttgat tctagatttg ttttaactaa ttaaaggagg aataacatat 1320
 ggттаacgсg ttggaattcg agctcactag tgtcgacctg cagggtacca tggaagctta 1380
 ctсgaggatc cсgсgaaaga agaagaagaa gaagaaagcc cgaaaggaag ctgagttggc 1440
 tgctgccacc gctgagcaat aactagcata accccttggg gcctctaaac gggctcttgag 1500
 ggggttttttg ctgaaaggag gaaccgctct tcacgctctt cacgc 1545

<210> 24

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
 PEPTIDE

<400> 24

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
 1 5 10

<210> 25

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
 PEPTIDE

<400> 25

Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 26

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
 PEPTIDE

<220>

<223> At position 15, Xaa=a linker sequence of 1 to 20
amino acids

<400> 26

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Xaa Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 27

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>

<223> At position 15, Xaa=a linker sequence of 1 to 20
amino acids

<400> 27

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala Xaa Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
20 25

<210> 28

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>

<223> At position 9 disulfide linkage with residue 24

<220>

<223> At position 24 disulfide linkage with residue 9

<400> 28

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Xaa Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
20 25

<210> 29

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>

<223> At position 16 bromoacetyl group linked to
sidechain

<400> 29

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Xaa Lys
1 5 10 15

Xaa Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 30

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>

<223> At position 16 polyethylene glycol linked to
sidechain

<400> 30

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Xaa Lys
1 5 10 15

Xaa Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 31
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>
<223> At position 9 disulfide bond to residue 9 of a
separate identical sequence

<400> 31
Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Xaa Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 32
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<220>
<223> At position 24 disulfide bond to residue 9 of a
separate identical sequence

<400> 32
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Xaa Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
20 25

<210> 33
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 33
Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5

<210> 34
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 34
Thr Leu Arg Glu Trp Leu
1 5

<210> 35
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 35
Gly Arg Val Arg Asp Gln Val Ala Gly Trp
1 5 10

<210> 36

<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 36

Gly Arg Val Lys Asp Gln Ile Ala Gln Leu
1 5 10

<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Description of
Artificial SequenceTPO-MIMETIC PEPTIDE

<400> 37

Gly Val Arg Asp Gln Val Ser Trp Ala Leu
1 5 10

<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 38

Glu Ser Val Arg Glu Gln Val Met Lys Tyr
1 5 10

<210> 39
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 39

Ser Val Arg Ser Gln Ile Ser Ala Ser Leu
1 5 10

<210> 40

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 40

Gly Val Arg Glu Thr Val Tyr Arg His Met
1 5 10

<210> 41

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 41

Gly Val Arg Glu Val Ile Val Met His Met Leu
1 5 10

<210> 42

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

PEPTIDE

<400> 42

Gly Arg Val Arg Asp Gln Ile Trp Ala Ala Leu
1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 43

Ala Gly Val Arg Asp Gln Ile Leu Ile Trp Leu
1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 44

Gly Arg Val Arg Asp Gln Ile Met Leu Ser Leu
1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 45

Gly Arg Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5 10

<210> 46

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 46

Cys Thr Leu Arg Gln Trp Leu Gln Gly Cys
1 5 10

<210> 47

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 47

Cys Thr Leu Gln Glu Phe Leu Glu Gly Cys
1 5 10

<210> 48

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 48

Cys Thr Arg Thr Glu Trp Leu His Gly Cys
1 5 10

<210> 49
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 49
Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys
1 5 10

<210> 50
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-TMP

<400> 50
Cys Thr Leu Arg Glu Trp Val Phe Ala Gly Leu Cys
1 5 10

<210> 51
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-TMP

<400> 51
Cys Thr Leu Arg Gln Trp Leu Ile Leu Leu Gly Met Cys
1 5 10

<210> 52
<211> 14
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 52

Cys	Thr	Leu	Ala	Glu	Phe	Leu	Ala	Ser	Gly	Val	Glu	Gln	Cys
1				5					10				

<210> 53

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 53

Cys	Ser	Leu	Gln	Glu	Phe	Leu	Ser	His	Gly	Gly	Tyr	Val	Cys
1				5					10				

<210> 54

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 54

Cys	Thr	Leu	Arg	Glu	Phe	Leu	Asp	Pro	Thr	Thr	Ala	Val	Cys
1				5					10				

<210> 55

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 55

Cys Thr Leu Lys Glu Trp Leu Val Ser His Glu Val Trp Cys
1 5 10

<210> 56

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 56

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10

<210> 57

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 57

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Cys
1 5 10

<210> 58

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 58

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Cys

1

5

10

<210> 59

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 59

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 60

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 60

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 61

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 61

Arg Glu Gly Pro Thr Leu Arg Gln Trp Met
1 5 10

<210> 62
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 62
Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10

<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 63
Glu Arg Gly Pro Phe Trp Ala Lys Ala Cys
1 5 10

<210> 64
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 64
Arg Glu Gly Pro Arg Cys Val Met Trp Met
1 5 10

<210> 65
<211> 14

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 65

Cys Gly Thr Glu Gly Pro Thr Leu Ser Thr Trp Leu Asp Cys
1 5 10

<210> 66

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 66

Cys Glu Gln Asp Gly Pro Thr Leu Leu Glu Trp Leu Lys Cys
1 5 10

<210> 67

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 67

Cys Glu Leu Val Gly Pro Ser Leu Met Ser Trp Leu Thr Cys
1 5 10

<210> 68

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 68

Cys Leu Thr Gly Pro Phe Val Thr Gln Trp Leu Tyr Glu Cys
1 5 10

<210> 69

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 69

Cys Arg Ala Gly Pro Thr Leu Leu Glu Trp Leu Thr Leu Cys
1 5 10

<210> 70

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 70

Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10

<210> 71

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 71

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10

<210> 72

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 72

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10

<210> 73

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 73

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10

<210> 74

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 74

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys

1

5

10

15

<210> 75

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 75

Gly Gly Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys Gly Gly
1 5 10 15

<210> 76

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 76

Gly Gly Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10 15

Gly Gly

<210> 77

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 77

Gly Asn Ala Asp Gly Pro Thr Leu Arg Gln Trp Leu Glu Gly Arg Arg

1

5

10

15

Pro Lys Asn

<210> 78

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 78

Leu Ala Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu His Gly Asn Gly

1

5

10

15

Arg Asp Thr

<210> 79

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 79

His Gly Arg Val Gly Pro Thr Leu Arg Glu Trp Lys Thr Gln Val Ala

1

5

10

15

Thr Lys Lys

<210> 80

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 80

Thr	Ile	Lys	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Lys	Ser	Arg	Glu	His
1				5					10					15	

Thr Ser

<210> 81

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 81

Ile	Ser	Asp	Gly	Pro	Thr	Leu	Lys	Glu	Trp	Leu	Ser	Val	Thr	Arg	Gly
1				5					10					15	

Ala Ser

<210> 82

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 82

Ser	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Glu	Trp	Leu	Thr	Ser	Arg	Thr	Pro
1				5					10					15	

His Ser

<210> 83
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 83
Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
1 5 10

<210> 84
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 84
Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Tyr Xaa
1 5 10 15

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
20 25

<210> 85
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>
<223> At position 15, Xaa=a linker sequence of 1 to 20
amino acids

<400> 85

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Xaa Tyr
 1 5 10 15

Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 20 25

<210> 86
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EPO-MIMETIC
 PEPTIDE

<220>
 <223> At position 15 linked through epsilon amine to
 lysyl, which is linked to a separate identical
 sequence through that sequence's alpha amine

<400> 86
 Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 87
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EPO-MIMETIC
 PEPTIDE

<400> 87
 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly
 20

<210> 88
 <211> 20

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 88

Gly	Gly	Asp	Tyr	His	Cys	Arg	Met	Gly	Pro	Leu	Thr	Trp	Val	Cys	Lys
1				5				10					15		

Pro Leu Gly Gly
20

<210> 89

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 89

Gly	Gly	Val	Tyr	Ala	Cys	Arg	Met	Gly	Pro	Ile	Thr	Trp	Val	Cys	Ser
1				5				10					15		

Pro Leu Gly Gly
20

<210> 90

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 90

Val	Gly	Asn	Tyr	Met	Cys	His	Phe	Gly	Pro	Ile	Thr	Trp	Val	Cys	Arg
1				5				10					15		

Pro Gly Gly Gly

<210> 91
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EPO-MIMETIC
 PEPTIDE

<400> 91
 Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
 1 5 10 15
 Tyr Lys Gly Gly
 20

<210> 92
 <211> 40
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:EPO-MIMETIC
 PEPTIDE

<400> 92
 Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15
 Pro Gln Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
 20 25 30
 Trp Val Cys Lys Pro Gln Gly Gly
 35 40

<210> 93
 <211> 41
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>

<223> At position 21, Xaa=a linker sequence of 1 to 20
amino acids

<400> 93

Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu	Thr	Trp	Val	Cys	Lys
1				5					10					15	

Pro	Gln	Gly	Gly	Xaa	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu
		20					25						30		

Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly
		35					40	

<210> 94

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 94

Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu	Thr	Trp	Val	Cys	Lys
1				5					10					15	

Pro	Gln	Gly	Gly	Ser	Ser	Lys
		20				

<210> 95

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDE

<400> 95

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Ser Ser Lys Gly Gly Thr Tyr Ser Cys His Phe Gly
 20 25 30

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys
 35 40 45

<210> 96

<211> 47

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
 PEPTIDE

<220>

<223> At position 24, Xaa=a linker sequence of 1 to 20
 amino acids

<400> 96

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Ser Ser Lys Xaa Gly Gly Thr Tyr Ser Cys His Phe
 20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys
 35 40 45

<210> 97

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
 PEPTIDE

<220>

<223> At position 22 linked through epsilon amine to
 lysyl, which is linked to a separate identical

sequence through that sequence's alpha amine

<400> 97

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser
20

<210> 98

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>

<223> At position 23 biotin linked to the sidechain
through a linker

<400> 98

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 99

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:G-CSF MIMETIC
PEPTIDE

<220>

<223> At position 4 disulfide bond to residue 4 of a
separate identical sequence

<400> 99

Glu Glu Asp Cys Lys

1

5

<210> 100

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:G-CSF MIMETIC
PEPTIDE

<220>

<223> At position 4, Xaa is an isoteric ethylene spacer
linked to a separate identical sequence

<400> 100

Glu Glu Asp Xaa Lys

1

5

<210> 101

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:G-CSF MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is a pyroglutamic acid residue

<220>

<223> At position 4, Xaa is an isoteric ethylene spacer
linked to a separate identical sequence

<400> 101

Xaa Glu Asp Xaa Lys

1

5

<210> 102

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is a picolinic acid residue

<220>

<223> At position 4, Xaa is an isoteric ethylene spacer
linked to a separate identical sequence

<400> 102

Xaa Ser Asp Xaa Lys
1 5

<210> 103

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>

<223> At position 6, Xaa=a linker sequence of 1 to 20
amino acids

<400> 103

Glu Glu Asp Cys Lys Xaa Glu Glu Asp Cys Lys
1 5 10

<210> 104

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>

<223> At position 6, Xaa=a linker sequence of 1 to 20
amino acids

<400> 104

Glu Glu Asp Xaa Lys Xaa Glu Glu Asp Xaa Lys
1 5 10

<210> 105

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTIVIRAL (HBV)
PEPTIDE

<400> 105

Leu Leu Gly Arg Met Lys
1 5

<210> 106

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 106

Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr
1 5 10

<210> 107

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 107

Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr

1 5 10

<210> 108

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 108

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr

1 5 10

<210> 109

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 109

Phe Cys Ala Ser Glu Asn His Cys Tyr

1 5

<210> 110

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 110

Tyr Cys Ala Ser Glu Asn His Cys Tyr

1 5

<210> 111
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 111
Phe Cys Asn Ser Glu Asn His Cys Tyr
1 5

<210> 112
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 112
Phe Cys Asn Ser Glu Asn Arg Cys Tyr
1 5

<210> 113
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 113
Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr
1 5 10

<210> 114
<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 114

Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe
1 5 10

<210> 115

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 115

Phe Cys Val Ser Asn Asp Arg Cys Tyr
1 5

<210> 116

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 116

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr
1 5 10

<210> 117

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 117

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr
1 5

<210> 118

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 118

Tyr Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 119

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 119

Phe Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 120

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 120

Tyr Cys Trp Ser Gln Asn Leu Cys Tyr
1 5

<210> 121
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 121
Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr
1 5 10

<210> 122
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 122
Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr
1 5

<210> 123
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ANTAGONIST

<400> 123
Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr
1 5

<210> 124

<211> 37
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 124

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa
35

<210> 125
<211> 15
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CTLA4-MIMETIC
PEPTIDE

<400> 125

Gly Phe Val Cys Ser Gly Ile Phe Ala Val Gly Val Gly Arg Cys
1 5 10 15

<210> 126
<211> 15
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CTLA4-MIMETIC
PEPTIDE

<400> 126

Ala Pro Gly Val Arg Leu Gly Cys Ala Val Leu Gly Arg Tyr Cys
1 5 10 15

<210> 127

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C3B ANTAGONIST

<400> 127

Ile	Cys	Val	Val	Gln	Asp	Trp	Gly	His	His	Arg	Cys	Thr	Ala	Gly	His
1				5				10						15	

Met	Ala	Asn	Leu	Thr	Ser	His	Ala	Ser	Ala	Ile
			20					25		

<210> 128

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C3B ANTAGONIST
PEPTIDE

<400> 128

Ile	Cys	Val	Val	Gln	Asp	Trp	Gly	His	His	Arg	Cys	Thr
1				5				10				

<210> 129

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C3B ANTAGONIST
PEPTIDE

<400> 129

Cys	Val	Val	Gln	Asp	Trp	Gly	His	His	Ala	Cys
1				5				10		

<210> 130
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 130
Thr Phe Ser Asp Leu Trp
1 5

<210> 131
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 131
Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 132
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 132
Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 133
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 133

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 134

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 134

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 135

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 135

Met Pro Arg Phe Met Asp Tyr Trp Glu Gly Leu Asn
1 5 10

<210> 136

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C3B ANTAGONIST

<400> 136

Val Gln Asn Phe Ile Asp Tyr Trp Thr Gln Gln Phe
1 5 10

<210> 137

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 137

Thr Gly Pro Ala Phe Thr His Tyr Trp Ala Thr Phe
1 5 10

<210> 138

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 138

Ile Asp Arg Ala Pro Thr Phe Arg Asp His Trp Phe Ala Leu Val
1 5 10 15

<210> 139

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 139

Pro Arg Pro Ala Leu Val Phe Ala Asp Tyr Trp Glu Thr Leu Tyr
1 5 10 15

<210> 140

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 140

Pro Ala Phe Ser Arg Phe Trp Ser Asp Leu Ser Ala Gly Ala His
1 5 10 15

<210> 141

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 141

Pro Ala Phe Ser Arg Phe Trp Ser Lys Leu Ser Ala Gly Ala His
1 5 10 15

<210> 142

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 142

Pro Xaa Phe Xaa Asp Tyr Trp Xaa Xaa Leu
1 5 10

<210> 143
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 143
Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 144
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 144
Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 145
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 145
Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 146
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 146

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 147

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 147

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 148

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 148

Asp Ile Thr Trp Asp Glu Leu Trp Lys Ile Met Asn
1 5 10

<210> 149

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 149

Asp Tyr Thr Trp Phe Glu Leu Trp Asp Met Met Gln
1 5 10

<210> 150

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 150

Gln Ile Thr Trp Ala Gln Leu Trp Asn Met Met Lys
1 5 10

<210> 151

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 151

Asp Met Thr Trp His Asp Leu Trp Thr Leu Met Ser
1 5 10

<210> 152

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 152

Asp	Tyr	Ser	Trp	His	Asp	Leu	Trp	Glu	Met	Met	Ser
1				5					10		

<210> 153

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 153

Glu	Ile	Thr	Trp	Asp	Gln	Leu	Trp	Glu	Val	Met	Asn
1				5					10		

<210> 154

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MDM/HDM
ANTAGONIST PEPTIDE

<400> 154

His	Val	Ser	Trp	Glu	Gln	Leu	Trp	Asp	Ile	Met	Asn
1				5					10		

<210> 155

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 155

His Ile Thr Trp Asp Gln Leu Trp Arg Ile Met Thr

1

5

10

<210> 156

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 156

Arg Asn Met Ser Trp Leu Glu Leu Trp Glu His Met Lys

1

5

10

<210> 157

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN

<400> 157

Ala Glu Trp Thr Trp Asp Gln Leu Trp His Val Met Asn Pro Ala Glu

1

5

10

15

Ser Gln

<210> 158

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN

<400> 158

His Arg Ala Glu Trp Leu Ala Leu Trp Glu Gln Met Ser Pro

1

5

10

<210> 159

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 159

Lys Lys Glu Asp Trp Leu Ala Leu Trp Arg Ile Met Ser Val
1 5 10

<210> 160

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN

<400> 160

Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 161

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN

<400> 161

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 162

<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN

<400> 162

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 163

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 163

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 164

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 164

Ser Cys Val Lys Trp Gly Lys Lys Glu Phe Cys Gly Ser
1 5 10

<210> 165

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN

<400> 165

Ser Cys Trp Lys Tyr Trp Gly Lys Glu Cys Gly Ser
1 5 10

<210> 166

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 166

Ser Cys Tyr Glu Trp Gly Lys Leu Arg Trp Cys Gly Ser
1 5 10

<210> 167

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CALMODULIN
ANTAGONIST PEPTIDE

<400> 167

Ser Cys Leu Arg Trp Gly Lys Trp Ser Asn Cys Gly Ser
1 5 10

<210> 168

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 168

Ser Cys Trp Arg Trp Gly Lys Tyr Gln Ile Cys Gly Ser
1 5 10

<210> 169

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 169

Ser Cys Val Ser Trp Gly Ala Leu Lys Leu Cys Gly Ser
1 5 10

<210> 170

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 170

Ser Cys Ile Arg Trp Gly Gln Asn Thr Phe Cys Gly Ser
1 5 10

<210> 171

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 171

Ser Cys Trp Gln Trp Gly Asn Leu Lys Ile Cys Gly Ser
1 5 10

<210> 172
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 172
Ser Cys Val Arg Trp Gly Gln Leu Ser Ile Cys Gly Ser
1 5 10

<210> 173
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 173
Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr
1 5 10 15

Thr Met Leu Ala Lys
20

<210> 174
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:CALMODULIN

<400> 174
Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg Phe
1 5 10 15

Lys Lys

<210> 175

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN

<400> 175

Arg Lys Trp Gln Lys Thr Gly His Ala Val Arg Ala Ile Gly Arg Leu
1 5 10 15

Ser Ser

<210> 176

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 176

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 177

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 177

Lys Ile Trp Ser Ile Leu Ala Pro Leu Gly Thr Thr Leu Val Lys Leu

1

5

10

15

Val Ala

<210> 178

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 178

Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu

1

5

10

<210> 179

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 179

Leu Lys Trp Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys

1

5

10

15

Leu Leu

<210> 180

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 180

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys Thr Leu Ser His Phe Ser
1 5 10 15

Val

<210> 181

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 181

Ala Glu Trp Pro Ser Pro Thr Arg Val Ile Ser Thr Thr Tyr Phe Gly
1 5 10 15

Ser

<210> 182

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 182

Ala Glu Leu Ala His Trp Pro Pro Val Lys Thr Val Leu Arg Ser Phe
1 5 10 15

Thr

<210> 183

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 183

Ala Glu Gly Ser Trp Leu Gln Leu Leu Asn Leu Met Lys Gln Met Asn
1 5 10 15

Asn

<210> 184

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CALMODULIN
ANTAGONIST PEPTIDE

<400> 184

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys
1 5 10

<210> 185

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:VINCULIN-BINDING PEPTIDE

<400> 185

Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Gly Val Ser
1 5 10 15

Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
20 25

<210> 186
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:VINCULIN-BINDING PEPTIDE

<400> 186
Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Arg Val Ser
1 5 10 15
Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
20 25

<210> 187
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VINCULIN
BINDING PEPTIDE

<400> 187
Ser Arg Gly Val Asn Phe Ser Glu Trp Leu Tyr Asp Met Ser Ala Ala
1 5 10 15
Met Lys Glu Ala Ser Asn Val Phe Pro Ser Arg Arg Ser Arg
20 25 30

<210> 188
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VINCULIN
BINDING PEPTIDE

<400> 188
Ser Ser Gln Asn Trp Asp Met Glu Ala Gly Val Glu Asp Leu Thr Ala

1 5 10 15

Ala Met Leu Gly Leu Leu Ser Thr Ile His Ser Ser Ser Arg
20 25 30

<210> 189
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VINCULIN
BINDING PEPTIDE

<400> 189
Ser Ser Pro Ser Leu Tyr Thr Gln Phe Leu Val Asn Tyr Glu Ser Ala
1 5 10 15

Ala Thr Arg Ile Gln Asp Leu Leu Ile Ala Ser Arg Pro Ser Arg
20 25 30

<210> 190
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VINCULIN
BINDING PEPTIDE

<400> 190
Ser Ser Thr Gly Trp Val Asp Leu Leu Gly Ala Leu Gln Arg Ala Ala
1 5 10 15

Asp Ala Thr Arg Thr Ser Ile Pro Pro Ser Leu Gln Asn Ser Arg
20 25 30

<210> 191
<211> 18
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VINCULIN
BINDING PEPTIDE

<400> 191

Asp Val Tyr Thr Lys Lys Glu Leu Ile Glu Cys Ala Arg Arg Val Ser
1 5 10 15

Glu Lys

<210> 192

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C4BP-BINDING
PEPTIDE

<400> 192

Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile
1 5 10 15

Asp Tyr Asn Asn Val Ser
20

<210> 193

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:C4BP-BINDING
PEPTIDE

<400> 193

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala
1 5 10 15

Glu Gly Trp His Val Asn
20

<210> 194
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:C4BP-BINDING
PEPTIDE

<400> 194
Leu Val Thr Val Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala
1 5 10 15
Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His
20 25 30
Val Asn

<210> 195
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:C4BP-BINDING
PEPTIDE

<400> 195
Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser
1 5 10

<210> 196
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 196
Ala Glu Pro Met Pro His Ser Leu Asn Phe Ser Gln Tyr Leu Trp Tyr

1

5

10

15

Thr

<210> 197

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 197

Ala Glu His Thr Tyr Ser Ser Leu Trp Asp Thr Tyr Ser Pro Leu Ala
1 5 10 15

Phe

<210> 198

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:VINCULIN-BINDING PEPTIDE

<400> 198

Ala Glu Leu Asp Leu Trp Met Arg His Tyr Pro Leu Ser Phe Ser Asn
1 5 10 15

Arg

<210> 199

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 199

Ala	Glu	Ser	Ser	Leu	Trp	Thr	Arg	Tyr	Ala	Trp	Pro	Ser	Met	Pro	Ser
1				5					10					15	

Tyr

<210> 200

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 200

Ala	Glu	Trp	His	Pro	Gly	Leu	Ser	Phe	Gly	Ser	Tyr	Leu	Trp	Ser	Lys
1				5					10					15	

Thr

<210> 201

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 201

Ala	Glu	Pro	Ala	Leu	Leu	Asn	Trp	Ser	Phe	Phe	Phe	Asn	Pro	Gly	Leu
1				5					10					15	

His

<210> 202
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 202
Ala Glu Trp Ser Phe Tyr Asn Leu His Leu Pro Glu Pro Gln Thr Ile
1 5 10 15

Phe

<210> 203
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 203
Ala Glu Pro Leu Asp Leu Trp Ser Leu Tyr Ser Leu Pro Pro Leu Ala
1 5 10 15

Met

<210> 204
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 204
Ala Glu Pro Thr Leu Trp Gln Leu Tyr Gln Phe Pro Leu Arg Leu Ser

1

5

10

15

Gly

<210> 205

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 205

Ala Glu Ile Ser Phe Ser Glu Leu Met Trp Leu Arg Ser Thr Pro Ala

1

5

10

15

Phe

<210> 206

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 206

Ala Glu Leu Ser Glu Ala Asp Leu Trp Thr Thr Trp Phe Gly Met Gly

1

5

10

15

Ser

<210> 207

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 207

Ala Glu Ser Ser Leu Trp Arg Ile Phe Ser Pro Ser Ala Leu Met Met

1

5

10

15

Ser

<210> 208

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 208

Ala Glu Ser Leu Pro Thr Leu Thr Ser Ile Leu Trp Gly Lys Glu Ser

1

5

10

15

Val

<210> 209

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 209

Ala Glu Thr Leu Phe Met Asp Leu Trp His Asp Lys His Ile Leu Leu

1

5

10

15

Thr

<210> 210
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 210
Ala Glu Ile Leu Asn Phe Pro Leu Trp His Glu Pro Leu Trp Ser Thr
1 5 10 15

Glu

<210> 211
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 211
Ala Glu Ser Gln Thr Gly Thr Leu Asn Thr Leu Phe Trp Asn Thr Leu
1 5 10 15

Arg

<210> 212
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa is V, L, I, E, P, G, Y, M, T,

or D

<220>

<223> At position 2, Xaa is Y, W or F

<220>

<223> At position 3, Xaa is E, F, V, W or Y

<220>

<223> At position 5, Xaa is P or azetidine

<220>

<223> At position 7, Xaa is S, A, V or L

<220>

<223> At position 8, Xaa is M, F, V, R, Q, K, T, S, D,
L, I or E

<220>

<223> At position 9, Xaa is E, L, W, V, H, I, G, A, D,
L, Y, N, Q or P

<400> 212

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 213

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 213

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 214

<211> 18

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 214

Ser	Trp	Thr	Asp	Tyr	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Ile	Ser
1				5				10						15	

Gly Leu

<210> 215

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 215

Glu	Thr	Pro	Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5				10						15	

Tyr Ala Leu Pro Leu
20

<210> 216

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 216

Glu	Asn	Thr	Tyr	Ser	Pro	Asn	Trp	Ala	Asp	Ser	Met	Tyr	Trp	Gln	Pro
1				5				10						15	

Tyr Ala Leu Pro Leu

<210> 217
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 217
 Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 218
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 218
 Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 219
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 219

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 220

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 220

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10

<210> 221

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 221

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 222

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, optionally acetylated at N-terminus

<220>

<223> At position 10, Xaa=azetidine

<400> 222

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 223

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11, Xaa=azetidine

<400> 223

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Pro	Tyr	Gln	Xaa	Tyr
1				5					10		

<210> 224

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 224

Phe	Ala	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 225
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

 <220>
 <223> At position 10, Xaa=azetidine

 <400> 225
 Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 226
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

 <220>
 <223> At position 10, Xaa=azetidine

 <400> 226
 Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 227
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

 <220>
 <223> At position 10, Xaa=azetidine

<400> 227

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 228

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, optionally acetylated at N-terminus

<220>

<223> At position 10, Xaa=azetidine

<400> 228

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 229

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, products="MeGly"

<220>

<223> At position 10, Xaa=azetidine

<400> 229

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 230
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<220>
 <223> At position 6, Xaa=MeGly

 <220>
 <223> At position 10, Xaa=azetidine

<400> 230
 Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 231
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 231
 Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
 1 5 10

<210> 232
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 232
 Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr

1

5

10

<210> 233

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 233

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 234

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 234

Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 235

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 235

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 236

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, Xaa=Aib

<220>

<223> At position 10, Xaa=azetidine

<400> 236

Phe	Glu	Trp	Thr	Pro	Xaa	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 237

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=MeGly

<220>

<223> At position 10, Xaa=azetidine

<400> 237

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 238

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11, amino group added at C-terminus

<400> 238

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 239

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11, amino group added at C-terminus

<400> 239

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10

<210> 240

<211> 11

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 240
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 241
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, optionally acetylated at
N-terminus

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11 amino group added at C-terminus

<400> 241
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 242
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>

<223> At position 8, Xaa is a phyosphotyrosyl residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 242

Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr

1

5

10

<210> 243

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 243

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 244

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 244

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 245

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 245

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 246

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 246

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 247

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1 acetylated at N-terminus

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 247

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 248

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 248

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
1 5 10

<210> 249

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, Xaa is a sarcosine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 249

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 250

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 250

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
1 5 10

<210> 251

<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 251

Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
1 5 10

<210> 252

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 252

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 253

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 253

Phe	Glu	Trp	Thr	Pro	Val	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 254

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa is a pipecolic acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 254

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 255

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 255

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 256

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=MeGly

<220>

<223> At position 10, Xaa=azetidine

<400> 256

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 257

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 257

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 258

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is a 1-naphthylalanine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 258

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 259

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is a azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 259

Tyr	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 260

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 260

Phe	Glu	Trp	Val	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 261

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 261

Phe	Glu	Trp	Thr	Pro	Ser	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 262

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 262

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 263

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 263

Thr Lys Pro Arg
1

<210> 264

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 264

Arg Lys Ser Ser Lys
1 5

<210> 265

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 265

Arg Lys Gln Asp Lys
1 5

<210> 266

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 266

Asn Arg Lys Gln Asp Lys
1 5

<210> 267

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 267

Arg Lys Gln Asp Lys Arg
1 5

<210> 268

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<400> 268

Glu Asn Arg Lys Gln Asp Lys Arg Phe
1 5

<210> 269

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 269

Val Thr Lys Phe Tyr Phe
1 5

<210> 270

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 270

Val Thr Lys Phe Tyr
1 5

<210> 271

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 271

Val Thr Asp Phe Tyr
1 5

<210> 272
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 272
Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr
1 5 10 15

Arg

<210> 273
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 273
Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg
1 5 10 15

Thr

<210> 274
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MCA/MCPPROTEASE

INHIBITOR PEPTIDE

<400> 274

Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 275

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 275

Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 276

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 276

Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 277

<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 277

Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 278

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
PROTEASE INHIBITOR PEPTIDE

<400> 278

Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser
1 5 10 15

Ala Lys His Gly
20

<210> 279

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 279

Leu Leu Gly Arg Met Lys
1 5

<210> 280
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 280
Ala Leu Leu Gly Arg Met Lys Gly
1 5

<210> 281
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-HBV
PEPTIDE

<400> 281
Leu Asp Pro Ala Phe Arg
1 5

<210> 282
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 282
Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 283
<211> 7

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 283

Arg Glu Leu Pro Pro Leu Pro
1 5

<210> 284

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MSH3 ANTAGONIST

<400> 284

Ser Pro Leu Pro Pro Leu Pro
1 5

<210> 285

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 285

Gly Pro Leu Pro Pro Leu Pro
1 5

<210> 286

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 286

Arg Pro Leu Pro Ile Pro Pro

1

5

<210> 287

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MAST CELL
ANTAGONISTS/MAST CELL PROTEASE INHIBITOR

<400> 287

Arg Pro Leu Pro Ile Pro Pro

1

5

<210> 288

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 288

Arg Arg Leu Pro Pro Thr Pro

1

5

<210> 289

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 289

Arg Gln Leu Pro Pro Thr Pro

1

5

<210> 290
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 290
Arg Pro Leu Pro Ser Arg Pro
1 5

<210> 291
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 291
Arg Pro Leu Pro Thr Arg Pro
1 5

<210> 292
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 292
Ser Arg Leu Pro Pro Leu Pro
1 5

<210> 293
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 293

Arg Ala Leu Pro Ser Pro Pro

1

5

<210> 294

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 294

Arg Arg Leu Pro Arg Thr Pro

1

5

<210> 295

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 295

Arg Pro Val Pro Pro Ile Thr

1

5

<210> 296

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 296

Ile Leu Ala Pro Pro Val Pro

1

5

<210> 297
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 297
Arg Pro Leu Pro Met Leu Pro
1 5

<210> 298
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 298
Arg Pro Leu Pro Ile Leu Pro
1 5

<210> 299
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 299
Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 300
<211> 7
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 300

Arg Pro Leu Pro Ser Leu Pro

1

5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 301

Arg Pro Leu Pro Met Ile Pro

1

5

<210> 302

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 302

Arg Pro Leu Pro Leu Ile Pro

1

5

<210> 303

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 303

Arg Pro Leu Pro Pro Thr Pro
1 5

<210> 304

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 304

Arg Ser Leu Pro Pro Leu Pro
1 5

<210> 305

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 305

Arg Pro Gln Pro Pro Pro Pro
1 5

<210> 306

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 306

Arg Gln Leu Pro Ile Pro Pro
1 5

<210> 307

<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 307

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
1 5 10

<210> 308

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 308

Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 309

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 309

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa
1 5 10

<210> 310

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 310

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
1 5 10

<210> 311

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 311

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Pro Pro
1 5 10

<210> 312

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 312

Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 313

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 313

Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa
1 5 10

<210> 314
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 314
Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro
1 5 10

<210> 315
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 1, Xaa is an aliphatic amino acid
residue

<400> 315
Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro
1 5 10

<210> 316
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
<223> At position 4, Xaa is an aromatic amino acid
residue

<220>
<223> At position 9, Xaa is an aliphatic amino acid
residue

<400> 316

Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro
1 5 10

<210> 317

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 1, Xaa is a basic amino acid residue

<220>

<223> At position 4, Xaa is an aliphatic amino acid
residue

<400> 317

Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu
1 5 10

<210> 318

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 4, Xaa is an aliphatic amino acid
residue

<220>

<223> At position 6, Xaa is an aliphatic amino acid
residue

<220>

<223> At position 8, Xaa is a basic amino acid residue

<400> 318

Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro
 1 5 10

<210> 319
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 319
 Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu
 1 5 10

<210> 320
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
 <223> At positions 1, 3 and 6, Xaa is an aliphatic
 amino acid residue

<400> 320
 Xaa Pro Xaa Leu Pro Xaa Lys
 1 5

<210> 321
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>
 <223> At position 1, Xaa is a basic amino acid residue

<220>

<223> At position 2, Xaa is an aromatic amino acid
residue

<400> 321

Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro
1 5 10

<210> 322

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INHIBITOR OF
PLATELET AGGREGATION

<400> 322

Cys Xaa Xaa Arg Gly Asp Cys
1 5

<210> 323

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 323

Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 324

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 324

Pro Pro Val Pro Pro Arg
1 5

<210> 325
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTI-CANCER
PEPTIDE

<400> 325
Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa
1 5 10

<210> 326
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC
PEPTIDE

<400> 326
Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

<210> 327
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:p16-MIMETIC
PEPTIDE

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
 1 5 10 15

Asp Phe Ala Trp
 20

<210> 328
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:p16-MIMETIC
 PEPTIDE

<400> 328
 Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
 1 5 10 15

Leu Ile Phe Ser
 20

<210> 329
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 329
 Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
 1 5 10 15

Lys Arg Lys Pro
 20

<210> 330
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:p16-MIMETIC
PEPTIDE

<400> 330

Arg Arg Leu Ile Phe

1 5

<210> 331

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:p16-MIMETIC
PEPTIDE

<400> 331

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg

1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met

20 25 30

Lys Trp Lys Lys

35

<210> 332

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:p16-MIMETIC
PEPTIDE

<400> 332

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln

1 5 10 15

Asn Arg Arg Met Lys Trp Lys Lys

20

<210> 333
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE
LINKER

<400> 333
Gly Gly Gly Lys Gly Gly Gly Gly
1 5

<210> 334
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE
LINKER

<400> 334
Gly Gly Gly Asn Gly Ser Gly Gly
1 5

<210> 335
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:POLYGLYCINE
LINKER

<400> 335
Gly Gly Gly Cys Gly Gly Gly Gly
1 5

<210> 336
<211> 5

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:FC PCR PRIMER

<400> 336

Gly Pro Asn Gly Gly
1 5

<210> 337

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 337

Phe Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 338

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 338

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly Phe

<210> 339

<211> 50

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 339

Phe Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro
1 5 10 15

Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly
20 25 30

Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln
35 40 45

Gly Gly
50

<210> 340

<211> 50

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC

<400> 340

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe
20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly
35 40 45

Gly Phe
50

<210> 341

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 341

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu
1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 342

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 342

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 343

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 343

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 344

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 344

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 345

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 345

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 346

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 346

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
20 25 30

Ala

<210> 347

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 347

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
20 25 30

Arg Ala

<210> 348

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 348

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala

20

25

30

Ala Arg Ala
35

<210> 349

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 349

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 350

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 350

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 351
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 351
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15
Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln
20 25 30
Trp Leu Ala Ala Arg Ala
35

<210> 352
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 352
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30
Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 353
<211> 32
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 353

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 354

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 354

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu
20 25 30

Ala Ala Arg Ala
35

<210> 355

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 355

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu
20 25 30

Ala Ala Arg Ala
35

<210> 356

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 356

Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu
20 25 30

Ala Ala Arg Ala
35

<210> 357

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 357

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 358

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

PEPTIDES

<400> 358

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Asx Arg Ala Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu
20 25 30

Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 359

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

PEPTIDES

<400> 359

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 360

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 360

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1					5				10					15	

Gly	Lys	Pro	Glu	Gly	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg
			20					25						30	

Gln	Trp	Leu	Ala	Ala	Arg	Ala
						35

<210> 361

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 361

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1					5				10					15	

Gly	Cys	Pro	Glu	Gly	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg
			20					25						30	

Gln	Trp	Leu	Ala	Ala	Arg	Ala
						35

<210> 362

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 362

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 363

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC
PEPTIDES

<400> 363

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 364

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP PCR
PRIMER

<400> 364

aaaaaaggat cctcgagatt aagcagcagc agccagccac tgacgcagag tcggacc 57

<210> 365

<211> 39

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP PCR
PRIMER

<400> 365

aaaggtggag gtggtggtat cgaaggtccg actctgcgt

39

<210> 366

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 366

cagtggctgg ctgctcgtgc ttaatctcga ggatcctttt tt

42

<210> 367

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 367

aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60
taatctcgag gatccttttt t 81

<210> 368

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 368

ttcgatacca ccacctccac ctttaccggg agacagggag aggctcttct gc

52

<210> 369

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP-TMP

<400> 369

aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60

<210> 370

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:FC PCR PRIMER

<400> 370

acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc 48

<210> 371

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP-TMP
OLIGONUCLEOTIDE

<400> 371

ggtggtggag gtggcggcgg aggtattgag ggcccaacc ttcgccaatg gcttgcagca 60
cgcgca 66

<210> 372

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP-TMP
OLIGONUCLEOTIDE

<400> 372

aaaaaaagga tcctcgagat tatgcgcgtg ctgcaagcca ttggcgaagg gttgggcoct 60
caatacctcc gccgcc 76

<210> 373

<211> 126

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<220>

<221> CDS

<222> (1)..(126)

<400> 373

aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

gct gct cgt gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca 96
Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

acc ctt cgc caa tgg ctt gca gca cgc gca 126
Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 374

<211> 42

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<400> 374

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 375
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-MMP
INHIBITOR

<220>
<221> CDS
<222> (4)..(732)

<400> 375
ttt ttt cat atg atc gaa ggt ccg act ctg cgt cag tgg
Phe His Met Ile Glu Gly Pro Thr Leu Arg Gln Trp
1 5 10

39

<210> 376
<211> 12
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:Fc-MMP
INHIBITOR

<400> 376
Phe His Met Ile Glu Gly Pro Thr Leu Arg Gln Trp
1 5 10

<210> 377
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR
Fc

<220>
<221> CDS
<222> (4)..(753)

<400> 377

agc acg agc agc cag cca ctg acg cag agt cgg acc ttc gat cat atg 48
Thr Ser Ser Gln Pro Leu Thr Gln Ser Arg Thr Phe Asp His Met
1 5 10 15

<210> 378

<211> 15

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:MMP INHIBITOR
Fc

<400> 378

Thr Ser Ser Gln Pro Leu Thr Gln Ser Arg Thr Phe Asp His Met
1 5 10 15

<210> 379

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TMP-TMP-Fc
OLIGONUCLEOTIDE

<400> 379

ctggctgctc gtgctggtgg aggcggtggg gacaaaactc acaca 45

<210> 380

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 380

ctggctgctc gtgctggcgg tgggtggcgga gggggtggca ttgagggcc a 51

<210> 381

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 381

aagccattgg cgaagggttg ggccctcaat gccaccccct ccgccaccac cgcc 54

<210> 382

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 382

acccttcgcc aatggcttgc agcacgcgca gggggaggcg gtggggacaa aact 54

<210> 383

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 383

cccaccgcct cccctgcgc gtgctgc 27

<210> 384

<211> 189

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<220>

<221> CDS

<222> (10)..(189)

<400> 384

ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg

1

5

10

gct ggc ggt ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99

Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg

15

20

25

30

caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147

Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu

35

40

45

gct gct cgt gct ggt gga ggc ggt ggg gac aaa act cac aca 189

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr

50

55

60

<210> 385

<211> 60

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:INTEGRIN

BINDING PEPTIDE

<400> 385

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly

1

5

10

15

Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp

20

25

30

Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala

35

40

45

Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr

50

55

60

<210> 386

<211> 141

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN

BINDING PEPTIDE

<400> 386

ctaattccgc tctcacctac caaacaatgc cccctgcaa aaaataaatt catataaaaa 60
acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120
tggcgggtgat actgagcaca t 141

<210> 387

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 387

cgatttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac 55

<210> 388

<211> 872

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 388

ttatatttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt 60
gttagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg 120
gataatatat gagcacaanaa aagaaacat taacacaaga gcagcttgag gacgcacgtc 180
gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg 240
cagacaagat ggggatggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat 300
taaagtctta taacgccgca ttgcttacaa aaattctcaa agttagcgtt gaagaattta 360
gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact 420
tagaagttag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa 480
gcttagaacc tttaacaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag 540
tgattctgca ttctggcttg aggttgaagg taattccatg accgcaccaa caggctccaa 600
gccaagcttt cctgacggaa tggttaattct cgttgaccct gagcaggctg ttgagccagg 660
tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga 720
tagcggtcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga 780
gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggctg 840
atagactagt ggatccacta gtgtttctgc cc 872

<210> 389
<211> 1197
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 389

```
ggcggaaacc gacgtccatc gaatggtgca aaacctttcg cggtatggca tgatagcgcc 60
cggaagagag tcaattcagg gtggtgaatg tgaaaccagt aacgttatac gatgtcgag 120
agtatgccgg tgtctcttat cagaccgttt cccgcgtggt gaaccaggcc agccacgttt 180
ctgcgaaaac gcgggaaaaa gtcgaagcgg cgatggcggg gctgaattac attcccaacc 240
gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc 300
tggccctgca cgcgccgtcg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg 360
gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg 420
tgcacaatct tctcgcgcaa cgcgtcagtg ggctgatcat taactatccg ctggatgacc 480
aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttattt cttgatgtct 540
ctgaccagac acccatcaac agtattattt tctcccatga agacggtagc cgactgggcg 600
tggagcatct ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt 660
ctgtctcggc gcgtctgcgt ctggctggct ggcatataa tctcactcgc aatcaaattc 720
agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaaccatgc 780
aaatgctgaa tgagggcatc gttccactg cgatgctggt tgccaacgat cagatggcgc 840
tgggcgcaat gcgcgccatt accgagtcgg ggctgcgcgt tggcgcggat atctcggtag 900
tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac 960
aggattttcg cctgctgggg caaacccagc tggaccgctt gctgcaactc tctcagggcc 1020
aggcgggtgaa gggcaatcag ctgttgcccg tctcactggt gaaaagaaaa accaccctgg 1080
cgcccaatac gcaaaccgcc tctccccggc cgttggccga ttcattaatg cagctggcac 1140
gacaggtttc ccgactggaa agcggacagt aaggtacatc aggatccagg cacagga 1197
```

<210> 390
<211> 61
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP
OLIGONUCLEOTIDE

<400> 390

```
tatgaaaggt ggaggtggtg gtggaggtac ttactcttgc cacttcggcc cgctgacttg 60
g                                                                                      61
```

<210> 391
<211> 72

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP
OLIGONUCLEOTIDE

<400> 391

cggtttgcaa acccaagtca gcggggccgaa gtggcaagag taagtacctc caccaccacc 60
tccacctttc at 72

<210> 392

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP
OLIGONUCLEOTIDE

<400> 392

gtttgcaaac cgcaggggtgg cggcggcgggc ggcggtggta cctattcctg tcatttt 57

<210> 393

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP
OLIGONUCLEOTIDE

<400> 393

ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg 60

<210> 394

<211> 118

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP PCR
TEMPLATE

<220>

<221> CDS
<222> (2)..(118)

<400> 394

```
t atg aaa ggt gga ggt ggt ggt gga ggt act tac tct tgc cac ttc ggc 49
  Met Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly
      1           5           10           15

ccg ctg act tgg gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt  97
Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly
      20           25           30

ggt acc tat tcc tgt cat ttt 118
Gly Thr Tyr Ser Cys His Phe
      35
```

<210> 395

<211> 39

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-EMP PCR
TEMPLATE

<400> 395

```
Met Lys Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly
      1           5           10           15

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly
      20           25           30

Gly Thr Tyr Ser Cys His Phe
      35
```

<210> 396

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP PCR
PRIMER

<400> 396

```
gcagaagagc ctctccctgt ctccgggtaa aggtggaggt ggtggtggag gtacttactc 60
t                                                                 61
```

<210> 397

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP PCR
PRIMER

<400> 397

ctaattggat ccacgagatt aaccaccctg cggtttgcaa

40

<210> 398

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PRIMER

<400> 398

aacataagta cctgtaggat cg

22

<210> 399

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PRIMER

<400> 399

agagtaagta cctccaccac cacctccacc tttaaccgga gacagggaga ggctcttctg 60
c 61

<210> 400

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-Fc
OLIGONUCLEOTIDE

<400> 400

ggcccgtga cctgggtatg taagccacaa ggggggtggg gaggcggggg gtaatctcga 60
g 61

<210> 401

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-Fc
OLIGONUCLEOTIDE

<400> 401

gatcctcgag attaccccc gctccccca ccccttgtg gcttacatac 50

<210> 402

<211> 118

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-Fc PCR
TEMPLATE

<220>

<221> CDS

<222> (1)..(108)

<400> 402

gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc 48
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
1 5 10 15

tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg 96
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
20 25 30

gga ggc ggg ggg taatctcgag 118
Gly Gly Gly Gly
35

<210> 403

<211> 36

<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:EMP-Fc PCR
 TEMPLATE

<400> 403
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
 1 5 10 15

Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 20 25 30

Gly Gly Gly Gly
 35

<210> 404
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EMP-Fc PCR
 PRIMER

<400> 404
ttatttcata tgaaaggtgg taactattcc tgtcatttt 39

<210> 405
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EMP-Fc PCR
 PRIMER

<400> 405
tggacatgtg tgagttttgt cccccccgcc tccccacccc cct 43

<210> 406
<211> 43
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PRIMER

<400> 406

aggggggtggg ggaggcgggg gggacaaaac tcacacatgt cca

43

<210> 407

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PRIMER

<400> 407

gttattgctc agcgggtggca

20

<210> 408

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 408

ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaatatg 60

<210> 409

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 409

taaaagttaa aactcaaac tagaatcaaa tcgataaaaa a

41

<210> 410

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 410

ggaggtactt actcttgcca cttcggtccc ctgacttggg ttgcaaacc g 51

<210> 411

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 411

agtcagcggg ccgaagtggc aagagtaagt acctcccata ttttattcct ccttc 55

<210> 412

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 412

caggggtggcg gcggtggcg cggtggtacc tattcctgtc attttgccc gctgacctgg 60

<210> 413

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 413

aaaatgacag gaataggtac caccgcccgc gccgcccga cctgctggtt tgcaaaccga 60

<210> 414
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 414
gtatgtaagc cacaaggggg tgggggaggc gggggggaca aaactcacac atgtcca 57

<210> 415
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EMP-EMP-Fc
OLIGONUCLEOTIDE

<400> 415
agttttgtcc cccccgcctc cccaccccc ttgtggctta cataccagcgc tcagcggggc 60

<210> 416
<211> 228
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EMP-EMP-Fc PCR
TEMPLATE

<220>
<221> CDS
<222> (58)..(228)

<400> 416
ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat 57

atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc 105
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat 153

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 20 25 30

ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc 201
 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
 35 40 45

ggg ggg gac aaa act cac aca tgt cca 228
 Gly Gly Asp Lys Thr His Thr Cys Pro
 50 55

<210> 417

<211> 57

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:EMP-EMP-Fc PCR
 TEMPLATE

<400> 417

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 20 25 30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
 35 40 45

Gly Gly Asp Lys Thr His Thr Cys Pro
 50 55

<210> 418

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP-EMP PCR
 PRIMER

<400> 418

ctaattggat cctcgagatt aacccccttg tggcttacat 40

<210> 419

<211> 72

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 419

Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Gly Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70

<210> 420

<211> 62

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 420

Xaa Tyr Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

<210> 421
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<220>
<223> At position 2, Xaa is R, H, L or W

<220>
<223> At position 3, Xaa is M, F or I

<220>
<223> At position 6, Xaa is any of the 20 genetically
encoded amino acid residues or a D-stereoisomer
thereof

<220>
<223> At position 9, Xaa is D, E, I, L or V

<400> 421
Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys
1 5 10

<210> 422
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 422
Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro
1 5 10 15

Gln Gly Gly

<210> 423
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 423
Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 424
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 424
Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp
1 5 10 15

Ile Cys

<210> 425
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 425
Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys

1

5

10

15

Pro Gln

<210> 426

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 426

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15Pro Leu Arg Gly
20

<210> 427

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 427

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
1 5 10 15Arg Pro Ser Pro Lys Ala
20

<210> 428

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 428

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys

1

5

10

<210> 429

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 429

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys

1

5

10

<210> 430

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 430

Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr

1

5

10

15

Tyr

<210> 431

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 431

Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg
1 5 10 15

Thr

<210> 432

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 432

Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser
1 5 10 15

Ala

<210> 433

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 433

Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu
1 5 10

<210> 434

<211> 17

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 434

Ala	Glu	Ser	Thr	Tyr	His	His	Leu	Ser	Leu	Gly	Tyr	Met	Tyr	Thr	Leu
1					5					10				15	

Asn

<210> 435

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST
PEPTIDE

<400> 435

Tyr	His	Xaa	Leu	Xaa	Xaa	Gly	Tyr	Met	Tyr	Thr
1				5					10	

<210> 436

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
INHIBITOR

<400> 436

Arg	Asn	Arg	Gln	Lys	Thr
1				5	

<210> 437

<211> 4

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
INHIBITOR

<400> 437
Arg Asn Arg Gln
1

<210> 438
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
INHIBITOR

<400> 438
Arg Asn Arg Gln Lys
1 5

<210> 439
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
INHIBITOR

<400> 439
Asn Arg Gln Lys Thr
1 5

<210> 440
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP
INHIBITOR

<400> 440

Arg Gln Lys Thr

1

<210> 441

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 441

Arg Xaa Glu Thr Xaa Trp Xaa

1

5

<210> 442

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 442

Arg Xaa Glu Thr Xaa Trp Xaa

1

5

<210> 443

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 443

Arg Gly Asp Gly Xaa

1

5

<210> 444

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 444

Cys Arg Gly Asp Gly Xaa Cys

1

5

<210> 445

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 445

Cys Xaa Xaa Arg Leu Asp Xaa Xaa Cys

1

5

<210> 446

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 446

Cys Ala Arg Arg Leu Asp Ala Pro Cys

1

5

<210> 447

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 447

Cys Pro Ser Arg Leu Asp Ser Pro Cys

1

5

<210> 448

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 448

Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa

1

5

<210> 449

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 449

Cys Xaa Cys Arg Gly Asp Cys Xaa Cys

1

5

<210> 450
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 450
Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 451
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 451
Cys Asp Cys Arg Gly Asp Cys Leu Cys
1 5

<210> 452
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 452
Cys Leu Cys Arg Gly Asp Cys Ile Cys
1 5

<210> 453
<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 453
Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa
1 5

<210> 454
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 454
Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 455
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 455
Cys Trp Asp Asp Gly Trp Leu Cys
1 5

<210> 456
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 456

Cys Trp Asp Asp Leu Trp Trp Leu Cys

1

5

<210> 457

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 457

Cys Trp Asp Asp Gly Leu Met Cys

1

5

<210> 458

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 458

Cys Trp Asp Asp Gly Trp Met Cys

1

5

<210> 459

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 459

Cys Ser Trp Asp Asp Gly Trp Leu Cys

1

5

<210> 460

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:INTEGRIN-BINDING PEPTIDE

<400> 460

Cys Pro Asp Asp Leu Trp Trp Leu Cys

1

5

<210> 461

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC

PEPTIDE

<400> 461

Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly

1

5

10

15

Pro Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20

25

30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

35

40

<210> 462

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 462

Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu
1 5 10 15

<210> 463

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:SELECTIN-ANTAGONIST PEPTIDE

<400> 463

Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu
1 5 10 15

Asp

<210> 464

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 464

Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu
1 5 10 15

Thr Asn Glu

<210> 465

<211> 13

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 465

Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp
1 5 10

<210> 466

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 466

Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu
1 5 10 15

<210> 467

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 467

Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu
1 5 10 15

Thr Glu Glu

<210> 468

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 468

Ala	Glu	Asn	Trp	Ala	Asp	Gly	Glu	Pro	Asn	Asn	Lys	Xaa	Asn	Xaa	Glu
1				5					10					15	

Asp

<210> 469

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 469

Cys	Xaa	Xaa	Xaa	Tyr	Thr	Xaa	Leu	Val	Ala	Ile	Gln	Asn	Lys	Xaa	Glu
1				5					10					15	

<210> 470

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 470

Arg	Lys	Xaa	Xaa	Xaa	Xaa	Trp	Xaa	Trp	Val	Gly	Thr	Xaa	Lys	Xaa	Leu
1				5					10					15	

Thr Xaa Glu

<210> 471

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 471

Ala Xaa Asn Trp Xaa Xaa Xaa Glu Pro Asn Asn Xaa Xaa Xaa Glu Asp
1 5 10 15

<210> 472

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SELECTIN
ANTAGONIST PEPTIDE

<400> 472

Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa
1 5 10

<210> 473

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN-MIMETIC PEPTIDE

<220>

<223> At position 1, Xaa is asp-arg-met-pro-cys,
arg-met-pro-cys, met-pro-cys, pro-cys, or cys

<220>

<223> At position 2, Xaa is arg or lys

<220>

<223> At position 10, Xaa is ser or thr

<220>

<223> At position 12, xaa is cys-lys or cys

<400> 473

Xaa	Xaa	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Xaa	Ser	Xaa
1				5					10		

<210> 474

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN-MIMETIC PEPTIDE

<400> 474

Asp	Arg	Met	Pro	Cys	Arg	Asn	Phe	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser
1				5					10					15	

Cys Lys

<210> 475

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN-MIMETIC PEPTIDE

<400> 475

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1				5					10				15	

<210> 476

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN-MIMETIC PEPTIDE

<400> 476

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10

<210> 477

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN-MIMETIC PEPTIDE

<400> 477

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 478

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 478

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 479

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/

CORTISTATIN MIMETIC PEPTIDE

<400> 479

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 480

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 480

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 481

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 481

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10 15

<210> 482

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 482

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10

<210> 483

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 483

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 484

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 484

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 485

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 485

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 486

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 486

Asp	Arg	Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

Lys

<210> 487

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 487

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5				10					15	

<210> 488

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 488

Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5				10				

<210> 489
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 489
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

<210> 490
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 490
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 491
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 491
Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 492
<211> 17

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 492

Asp	Arg	Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

Lys

<210> 493

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 493

Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5				10					15	

<210> 494

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 494

Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5				10				

<210> 495

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 495

Asp	Arg	Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

<210> 496

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 496

Met	Pro	Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5				10					

<210> 497

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SOMATOSTATIN/
CORTISTATIN MIMETIC PEPTIDE

<400> 497

Cys	Lys	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5				10			

<210> 498

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CAP37
MIMETIC/LPS BINDING PEPTIDE

<400> 498

Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe
1 5 10 15
Val Met Thr Ala Ala Ser Cys Phe Gln
20 25

<210> 499

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CAP37
MIMETIC/LPS BINDING PEPTIDE

<400> 499

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
1 5 10 15
Ala Ala Ser Cys
20

<210> 500

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CAP37
MIMETIC/LPS BINDING PEPTIDE

<400> 500

Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly
1 5 10 15
Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val
20 25

<210> 501
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF-ANTAGONIST
PEPTIDE

<400> 501
Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp
1 5 10 15

Glu Ile

<210> 502
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 502
Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr
1 5 10 15

Val Lys

<210> 503
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ANTIPATHOGENIC
PEPTIDE

<400> 503
Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys

1

5

10

15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
 20 25 30

Gln

<210> 504

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTIPATHOGENIC
 PEPTIDE

<220>

<223> At positions 7, 18 and 19, D amino acid residue

<400> 504

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
 1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
 20 25 30

Glu

<210> 505

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTIPATHOGENIC
 PEPTIDE

<220>

<223> At positions 18 and 19, D amino acid residues

<400> 505

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys

1

5

10

15

Thr Leu Leu Ser Ala Val
20

<210> 506

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 7, 18 and 19, D amino acid residues

<400> 506

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 5 10 15

Thr Leu Leu Ser Ala Val
20

<210> 507

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 8, 19 and 20, D amino acid residues

<400> 507

Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe
1 5 10 15

Lys Thr Leu Leu Ser Ala Val
20

<210> 508

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 9, 20 and 21, D amino acid residues

<400> 508

Lys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu
1				5				10						15	

Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val
			20				

<210> 509

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 9, 20 and 21, D amino acid residues

<400> 509

Lys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu
1				5				10						15	

Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val
			20				

<210> 510

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 7, D amino acid residue

<400> 510

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser
1 5 10

<210> 511

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 511

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 512

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 5, 8, 17 and 23, D amino acid
residues

<400> 512

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 513

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 5, 8, 17 and 23, D amino acid
residues

<400> 513

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 514

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 5, 8, 17 and 21, D amino acid
residues

<400> 514

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg
20

<210> 515
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>
<223> At positions 2, 5, 14 and 18, D amino acid
residues

<400> 515
Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu Ile Ser Trp
1 5 10 15

Ile Lys Arg

<210> 516
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>
<223> At positions 3, 4, 8 and 10, D amino acid residues

<400> 516
Lys Leu Leu Leu Leu Lys Leu Leu Leu Lys
1 5 10

<210> 517
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<220>

<223> At positions 3, 4, 8 and 10, D amino acid residues

<400> 517

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 518

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 3, 4, 8 and 10, D amino acid residues

<400> 518

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 519

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 519

Lys Lys Leu Leu Lys Leu Lys Leu Lys Leu Lys Lys
1 5 10

<210> 520

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 520

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 521

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 521

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 522

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 522

Lys Leu Leu Leu Leu Lys
1 5

<210> 523

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<400> 523

Lys Leu Leu Leu Lys Leu Leu Lys
1 5

<210> 524

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 524

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 525

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 525

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 526

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 526

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 527

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 527

Lys Ala Ala Ala Lys Ala Ala Ala Lys Ala Ala Lys
1 5 10

<210> 528

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 528

Lys Val Val Val Lys Val Val Val Lys Val Val Lys
1 5 10

<210> 529

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 529

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
1 5 10

<210> 530

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 530

Lys Val Val Val Lys Val Lys Val Lys Val Lys
1 5 10

<210> 531

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 531

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
1 5 10

<210> 532

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 532

Lys Leu Ile Leu Lys Leu
1 5

<210> 533

<211> 6
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 533

Lys Val Leu His Leu Leu
1 5

<210> 534

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 534

Leu Lys Leu Arg Leu Leu
1 5

<210> 535

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 535

Lys Pro Leu His Leu Leu
1 5

<210> 536

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 536

Lys Leu Ile Leu Lys Leu Val Arg
1 5

<210> 537

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 537

Lys Val Phe His Leu Leu His Leu
1 5

<210> 538

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 538

His Lys Phe Arg Ile Leu Lys Leu
1 5

<210> 539

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<400> 539

Lys Pro Phe His Ile Leu His Leu
1 5

<210> 540

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 540

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 541

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 541

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 542

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 542

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 543

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 543

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Pro Lys
1 5 10

<210> 544

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 544

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Val Lys
1 5 10

<210> 545

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 545

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 546
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 546
Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 547
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 547
Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 548
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 548
Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 549

<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 549

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg
1 5 10

<210> 550

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 550

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg
1 5 10

<210> 551

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 551

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 552

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 552

Arg Ile Ala Val Lys Trp Arg Leu Arg Phe Ile Lys
1 5 10

<210> 553

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 553

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg
1 5 10

<210> 554

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 554

Lys Lys Ile Gly Trp Leu Ile Ile Arg Val Arg Arg
1 5 10

<210> 555

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<400> 555

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
1 5 10

<210> 556

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 556

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg Val Arg
1 5 10

<210> 557

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 557

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg Arg Val
1 5 10

<210> 558

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 558

Lys Ile Val Ile Arg Ile Arg Ala Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15

<210> 559

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
 PEPTIDE

<400> 559

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 560

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
 PEPTIDE

<400> 560

Lys Ile Gly Ile Lys Ala Arg Val Arg Ile Ile Arg Val Lys Ile Ile
 1 5 10 15

<210> 561

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
 PEPTIDE

<400> 561

Arg Ile Ile Val His Ile Arg Leu Arg Ile Ile His His Ile Arg Leu
 1 5 10 15

<210> 562
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 562
His Ile Gly Ile Lys Ala His Val Arg Ile Ile Arg Val His Ile Ile
1 5 10 15

<210> 563
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 563
Arg Ile Tyr Val Lys Ile His Leu Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 564
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 564
Lys Ile Gly His Lys Ala Arg Val His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 565

<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 565

Arg	Ile	Tyr	Val	Lys	Pro	His	Pro	Arg	Tyr	Ile	Lys	Lys	Ile	Arg	Leu
1				5					10					15	

<210> 566

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 566

Lys	Pro	Gly	His	Lys	Ala	Arg	Pro	His	Ile	Ile	Arg	Tyr	Lys	Ile	Ile
1				5					10					15	

<210> 567

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 567

Lys	Ile	Val	Ile	Arg	Ile	Arg	Ile	Arg	Leu	Ile	Arg	Ile	Arg	Ile	Arg
1				5					10					15	

Lys Ile Val

<210> 568

<211> 19
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 568

Arg	Ile	Ile	Val	Lys	Ile	Arg	Leu	Arg	Ile	Ile	Lys	Lys	Ile	Arg	Leu
1				5					10					15	

Ile Lys Lys

<210> 569
<211> 19
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 569

Lys	Ile	Gly	Trp	Lys	Leu	Arg	Val	Arg	Ile	Ile	Arg	Val	Lys	Ile	Gly
1				5					10					15	

Arg Leu Arg

<210> 570
<211> 25
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 570

Lys	Ile	Val	Ile	Arg	Ile	Arg	Ile	Arg	Leu	Ile	Arg	Ile	Arg	Ile	Arg
1				5					10					15	

Lys Ile Val Lys Val Lys Arg Ile Arg
20 25

<210> 571
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 571
Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys Ile Arg Lys Arg Val Ile Lys
20 25

<210> 572
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 572
Lys Ala Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
1 5 10 15

Arg Leu Arg Lys Ile Gly Trp Lys Lys Arg Val Arg Ile Lys
20 25 30

<210> 573
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<400> 573

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 574

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 574

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 575

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 575

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
1 5 10 15

Lys Ile Val

<210> 576

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC

PEPTIDE

<400> 576

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys

<210> 577

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 577

Arg Ile Tyr Val Ser Lys Ile Ser Ile Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 578

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 578

Lys Ile Val Ile Phe Thr Arg Ile Arg Leu Thr Ser Ile Arg Ile Arg
1 5 10 15

Ser Ile Val

<210> 579

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 579

Lys Pro Ile His Lys Ala Arg Pro Thr Ile Ile Arg Tyr Lys Met Ile
1 5 10 15

<210> 580

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, disulfide bond to position 26

<220>

<223> At position 26, disulfide bond to position 1

<400> 580

Xaa Cys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro
1 5 10 15

Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
20 25

<210> 581

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 581

Cys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro
1 5 10 15

Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
20 25

<210> 582
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 582
Cys Lys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser
1 5 10 15

Pro Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
20 25

<210> 583
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>
<223> At position 1, disulfide bond to position 17

<220>
<223> At position 17, disulfide bond to position 1

<400> 583
Xaa Cys Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
1 5 10 15

Cys

<210> 584

<211> 19
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, disulfide bond to position 19

<220>

<223> At position 19, disulfide bond to position 1

<400> 584

Xaa	Cys	Lys	Pro	Gly	His	Lys	Ala	Arg	Pro	His	Ile	Ile	Arg	Tyr	Lys
1					5				10					15	

Ile Ile Cys

<210> 585

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, disulfide bond to position 29

<220>

<223> At position 29, disulfide bond to position 1

<400> 585

Xaa	Cys	Arg	Phe	Ala	Val	Lys	Ile	Arg	Leu	Arg	Ile	Ile	Lys	Lys	Ile
1					5				10					15	

Arg	Leu	Ile	Lys	Lys	Ile	Arg	Lys	Arg	Val	Ile	Lys	Cys
				20				25				

<210> 586

<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 586

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys Cys
1 5 10

<210> 587

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 587

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 588

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 588

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys Cys
1 5 10

<210> 589

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 589

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 590

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 590

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
20 25

<210> 591

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 591

Asn Leu Glu His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu
1 5 10 15

Arg Lys Gln Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
20 25 30

<210> 592

<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is absent or is ala, val,
ala-val, val-ala, L-lys, D-lys, ala-lys, val-lys,
ala-val-lys, val-ala-lys, or an ornithinyl residue

<220>

<223> At position 2, Xaa is L-lys, D-lys or an
ornithinyl residue

<220>

<223> At position 3, Xaa is L-tyr, D-tyr, phe, trp or a
p-aminophenylalanyl residue

<220>

<223> At position 4, Xaa is a hydrophobic aliphatic
amino acid residue (X5), X5-leu, X5-norleucyl,
X5-D-ala, X5-asn-ser, X5-asn-ser-ile,
X5-asn-ser-tyr, X5-asn-ser-ile-leu,
X5-asn-ser-tyr-leu,

<220>

<223> or X5-asn-ser-tyr-leu-asn

<400> 592

Xaa Xaa Xaa Xaa

1

<210> 593

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is either absent, a hydrophobic

aliphatic residue (X5), X5-asn, tyr-X5, lys-X5,
lyx-S5-asn, lys-tyr-X5, lys-tyr-X5-as,
lys-lys-tyr-X5, lys-lys-tyr-X5-asn,
val-lys-lys-tyr-X5,

<220>

<223> val-ala-lys-lys-tyr-X5-asn, or
ala-val-lys-lys-tyr-X5-asn

<220>

<223> At position 3, Xaa is ile or tyr

<400> 593

Xaa Ser Xaa Leu Asn
1 5

<210> 594

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 1 and 6, Xaa are cross-linked amino
acid residues in which the sidechain linker group
is (CH₂)_m-Z-(CH₂)_n wherein Z is -CONH-, -NHCO-,
-S-S-, -S(CH₂)tCO-NH or -NH-CO(CH₂)tS-; m is 1 or
2

<220>

<223> when Z is -NH-CO- or -NH-CO(CH₂)tS-; n is 1 or 2
when Z is -NH-CO-, -S-S- or -NH-CO(CH₂)tS, or n is
2, 3 or 4 when Z is -CONH- or -S(CH₂)tCO-NH-

<220>

<223> At position 5, Xaa is a hydrophobic aliphatic
amino acid residue

<220>

<223> At position 7, Xaa is a covalent bond or Asn, Ser,
Ile, Tyr, Leu, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Tyr,
Asn-Ser-Ile-Leu, Asn-Ser-Tyr-Leu,
Asn-Ser-Ile-Leu-Asn or Asn-Ser-Tyr-Leu-Asn

<400> 594

Xaa Lys Lys Tyr Xaa Xaa Xaa

1

5

<210> 595

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 595

Lys Lys Tyr Leu

1

<210> 596

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 596

Asn Ser Ile Leu Asn

1

5

<210> 597

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 597

Lys Lys Tyr Leu

1

<210> 598

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 4, D amino acid residue

<400> 598

Lys Lys Tyr Ala

1

<210> 599

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 599

Ala Val Lys Lys Tyr Leu

1

5

<210> 600

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 600

Asn Ser Ile Leu Asn

1

5

<210> 601

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 601

Lys Lys Tyr Val

1

<210> 602

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 3, Xaa is a lauric acid residue

<400> 602

Ser Ile Xaa Asn

1

<210> 603

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 5, Xaa is a norleucyl residue

<400> 603

Lys Lys Tyr Leu Xaa

1 5

<210> 604

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 604

Asn Ser Tyr Leu Asn

1 5

<210> 605

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 605

Asn Ser Ile Tyr Asn

1 5

<210> 606

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 606

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn

1

5

10

<210> 607

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is a lauric acid residue

<400> 607

Xaa Lys Lys Tyr Leu

1

5

<210> 608

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 1, Xaa is a caproic acid residue

<400> 608

Xaa Lys Lys Tyr Leu

1

5

<210> 609

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 4, Xaa is a norleucyl residue

<400> 609

Lys Lys Tyr Xaa

1

<210> 610

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 610

Val Lys Lys Tyr Leu

1

5

<210> 611

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 611

Leu Asn Ser Ile Leu Asn

1

5

<210> 612

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 612

Tyr Leu Asn Ser Ile Leu Asn

1

5

<210> 613

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 613

Lys Lys Tyr Leu Asn

1

5

<210> 614

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 614

Lys Lys Tyr Leu Asn Ser

1

5

<210> 615

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 615

Lys Lys Tyr Leu Asn Ser Ile

1

5

<210> 616

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 616

Lys Lys Tyr Leu Asn Ser Ile Leu

1

5

<210> 617

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 617

Lys Lys Tyr Leu

1

<210> 618

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 618

Lys Lys Tyr Asp Ala

1

5

<210> 619
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 619
Ala Val Lys Lys Tyr Leu
1 5

<210> 620
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 620
Asn Ser Ile Leu Asn
1 5

<210> 621
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 621
Lys Lys Tyr Val
1

<210> 622
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>
<223> At position 3, Xaa is a lauric acid residue

<400> 622
Ser Ile Xaa Asn
1

<210> 623
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 623
Asn Ser Tyr Leu Asn
1 5

<210> 624
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 624
Asn Ser Ile Tyr Asn
1 5

<210> 625
<211> 5

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 5, Xaa is a norleucyl residue

<400> 625

Lys Lys Tyr Leu Xaa
1 5

<210> 626

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 626

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 627

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 627

Lys Lys Tyr Leu
1

<210> 628

<211> 5

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 628

Lys Lys Tyr Asp Ala
1 5

<210> 629

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 629

Ala Val Lys Lys Tyr Leu
1 5

<210> 630

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 630

Asn Ser Ile Leu Asn
1 5

<210> 631

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 631

Lys Lys Tyr Val

1

<210> 632

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 3, Xaa is a lauric acid residue

<400> 632

Ser Ile Xaa Asn

1

<210> 633

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 633

Leu Ala Lys Lys Tyr Leu

1

5

<210> 634

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 634

Cys Ala Pro Lys Lys Tyr Leu

1

5

<210> 635

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 4, Xaa is a norleucyl residue

<400> 635

Lys Lys Tyr Xaa

1

<210> 636

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 636

Val Lys Lys Tyr Leu

1

5

<210> 637

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 637

Leu Asn Ser Ile Leu Asn

1

5

<210> 638

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 638

Tyr Leu Asn Ser Ile Leu Asn

1

5

<210> 639

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 5, Xaa is a norleucyl residue

<400> 639

Lys Lys Tyr Leu Xaa

1

5

<210> 640

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 640

Lys Lys Tyr Leu Asn

1 5

<210> 641

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 641

Lys Lys Tyr Leu Asn Ser

1 5

<210> 642

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 642

Lys Lys Tyr Leu Asn Ser Ile

1 5

<210> 643

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 643

Lys Lys Tyr Leu Asn Ser Ile Leu

1

5

<210> 644

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 644

Lys Lys Lys Tyr Leu Asp

1

5

<210> 645

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 1, 6 disulfide cross-linked

<400> 645

Xaa Cys Lys Lys Tyr Leu Cys

1

5

<210> 646

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At positions 1, 6 cross-linked by S-CH2-CO

<400> 646

Cys Lys Lys Tyr Leu Lys

1

5

<210> 647

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<220>

<223> At position 4, D amino acid residue

<400> 647

Lys Lys Tyr Ala

1

<210> 648

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 648

Trp Trp Thr Asp Thr Gly Leu Trp

1

5

<210> 649

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 649

Trp Trp Thr Asp Asp Gly Leu Trp

1

5

<210> 650

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 650

Trp Trp Asp Thr Arg Gly Leu Trp Val Trp Thr Ile

1

5

10

<210> 651

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 651

Phe Trp Gly Asn Asp Gly Ile Trp Leu Glu Ser Gly

1

5

10

<210> 652

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 652

Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
1 5 10

<210> 653

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 653

Arg Trp Asp Asp Asn Gly Leu Trp Val Val Val Leu
1 5 10

<210> 654

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 654

Ser Gly Met Trp Ser His Tyr Gly Ile Trp Met Gly
1 5 10

<210> 655

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 655

Gly Gly Arg Trp Asp Gln Ala Gly Leu Trp Val Ala

1

5

10

<210> 656

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 656

Lys Leu Trp Ser Glu Gln Gly Ile Trp Met Gly Glu
1 5 10

<210> 657

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 657

Cys Trp Ser Met His Gly Leu Trp Leu Cys
1 5 10

<210> 658

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 658

Gly Cys Trp Asp Asn Thr Gly Ile Trp Val Pro Cys
1 5 10

<210> 659
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 659
Asp Trp Asp Thr Arg Gly Leu Trp Val Tyr
1 5 10

<210> 660
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 660
Ser Leu Trp Asp Glu Asn Gly Ala Trp Ile
1 5 10

<210> 661
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 661
Lys Trp Asp Asp Arg Gly Leu Trp Met His
1 5 10

<210> 662
<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 662

Gln Ala Trp Asn Glu Arg Gly Leu Trp Thr
1 5 10

<210> 663

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 663

Gln Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 664

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 664

Trp Asn Val His Gly Ile Trp Gln Glu
1 5

<210> 665

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 665

Ser Trp Asp Thr Arg Gly Leu Trp Val Glu
1 5 10

<210> 666

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 666

Asp Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 667

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 667

Ser Trp Gly Arg Asp Gly Leu Trp Ile Glu
1 5 10

<210> 668

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 668

Glu Trp Thr Asp Asn Gly Leu Trp Ala Leu
1 5 10

<210> 669

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 669

Ser Trp Asp Glu Lys Gly Leu Trp Ser Ala
1 5 10

<210> 670

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC
PEPTIDE

<400> 670

Ser Trp Asp Ser Ser Gly Leu Trp Met Asp
1 5 10

<210> 671

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 671

Ser His Leu Tyr Trp Gln Pro Tyr Ser Val Gln

1

5

10

<210> 672

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 672

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Leu Gln Thr

1

5

10

<210> 673

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 673

Arg Gly Asp Tyr Trp Gln Pro Tyr Ser Val Gln Ser

1

5

10

<210> 674

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 674

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr

1

5

10

<210> 675
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 675
Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 676
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 676
Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 677
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 677
Asn Met Val Tyr Trp Gln Pro Tyr Ser Ile Gln Thr
1 5 10

<210> 678
<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 678

Ser Val Val Phe Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 679

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 679

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 680

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 680

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 681

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 681

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg

1

5

10

<210> 682

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 682

Ser Pro Val Phe Trp Gln Pro Tyr Ser Ile Gln Ile

1

5

10

<210> 683

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 683

Trp Ile Glu Trp Trp Gln Pro Tyr Ser Val Gln Ser

1

5

10

<210> 684

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 684

Ser Leu Ile Tyr Trp Gln Pro Tyr Ser Leu Gln Met

1

5

10

<210> 685

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 685

Thr Arg Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg

1

5

10

<210> 686

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 686

Arg Cys Asp Tyr Trp Gln Pro Tyr Ser Val Gln Thr

1

5

10

<210> 687

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 687

Met Arg Val Phe Trp Gln Pro Tyr Ser Val Gln Asn

1

5

10

<210> 688

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 688

Lys Ile Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 689

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 689

Arg His Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 690

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 690

Ala Leu Val Trp Trp Gln Pro Tyr Ser Glu Gln Ile
1 5 10

<210> 691
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 691
Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 692
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 692
Trp Glu Gln Pro Tyr Ala Leu Pro Leu Glu
1 5 10

<210> 693
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 693
Gln Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 694
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 694

Asp Leu Arg Tyr Trp Gln Pro Tyr Ser Val Gln Val
1 5 10

<210> 695

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 695

Glu Leu Val Trp Trp Gln Pro Tyr Ser Leu Gln Leu
1 5 10

<210> 696

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 696

Asp Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Trp
1 5 10

<210> 697

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 697

Asn Gly Asn Tyr Trp Gln Pro Tyr Ser Phe Gln Val
1 5 10

<210> 698

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 698

Glu Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 699

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 699

Glu Leu Met Tyr Trp Gln Pro Tyr Ser Val Gln Glu
1 5 10

<210> 700

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 700

Asn Leu Leu Tyr Trp Gln Pro Tyr Ser Met Gln Asp
1 5 10

<210> 701

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 701

Gly Tyr Glu Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 702

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 702

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 703

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 703

Leu Ser Glu Gln Tyr Gln Pro Tyr Ser Val Gln Arg

1

5

10

<210> 704

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 704

Gly Gly Gly Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 705

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 705

Val Gly Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 706

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 706

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 707
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 707
Gln Ala Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 708
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 708
Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 709
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 709
Arg Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 710
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 710

Thr Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 711

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 711

Gly Arg Ile Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 712

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 712

Gly Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 713

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 713

Ala Arg Thr Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 714

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 714

Ala Arg Val Trp Trp Gln Pro Tyr Ser Val Gln Met
1 5 10

<210> 715

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 715

Arg Leu Met Phe Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 716

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 716

Glu Ser Met Trp Tyr Gln Pro Tyr Ser Val Gln Arg

1 5 10

<210> 717

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 717

His Phe Gly Trp Trp Gln Pro Tyr Ser Val His Met

1 5 10

<210> 718

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 718

Ala Arg Phe Trp Trp Gln Pro Tyr Ser Val Gln Arg

1 5 10

<210> 719

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 719

Arg Leu Val Tyr Trp Gln Pro Tyr Ala Pro Ile Tyr

1

5

10

<210> 720

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 720

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Tyr Gln Thr
1 5 10

<210> 721

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 721

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Leu Pro Ile
1 5 10

<210> 722

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 722

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Ala
1 5 10

<210> 723
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 723
Ser Arg Val Trp Tyr Gln Pro Tyr Ala Lys Gly Leu
1 5 10

<210> 724
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 724
Ser Arg Val Trp Tyr Gln Pro Tyr Ala Gln Gly Leu
1 5 10

<210> 725
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 725
Ser Arg Val Trp Tyr Gln Pro Tyr Ala Met Pro Leu
1 5 10

<210> 726
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 726

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Ala
1 5 10

<210> 727

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 727

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Leu Gly Leu
1 5 10

<210> 728

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 728

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Arg Glu Leu
1 5 10

<210> 729

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 729

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Arg Gln Pro
1 5 10

<210> 730

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 730

Ser Arg Val Trp Tyr Gln Pro Tyr Phe Val Gln Pro
1 5 10

<210> 731

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 731

Glu Tyr Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 732

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 732

Ile Pro Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 733

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 733

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 734

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 734

Asp Pro Leu Phe Trp Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 735

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 735

Ser Arg Gln Trp Val Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 736

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 736

Ile Arg Ser Trp Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 737

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 737

Arg Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 738

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 738

Arg Leu Leu Trp Val Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 739
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 739
Glu Tyr Arg Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 740
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 740
Asp Ala Tyr Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 741
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 741
Trp Ser Gly Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 742
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 742

Asn Ile Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 743

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 743

Thr Arg Asp Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 744

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 744

Asp Ser Ser Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 745

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 745

Ile Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 746

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 746

Asn Leu Arg Trp Asp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 747

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 747

Leu Pro Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 748

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 748

Asp Ser Tyr Trp Trp Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 749

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 749

Arg Ser Gln Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 750

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 750

Ala Arg Phe Trp Leu Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 751

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 751

Asn Ser Tyr Phe Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 752

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 752

Arg Phe Met Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 753

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 753

Ala His Leu Phe Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 754

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 754

Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 755
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 755
Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 756
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 756
Tyr Phe Gln Pro Tyr Ala Leu Gly Leu
1 5

<210> 757
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 757
Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 758
<211> 10

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 758

Arg Trp Trp Gln Pro Tyr Ala Thr Pro Leu
1 5 10

<210> 759

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 759

Gly Trp Tyr Gln Pro Tyr Ala Leu Gly Phe
1 5 10

<210> 760

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 760

Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu
1 5 10

<210> 761

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 761

Ile Trp Tyr Gln Pro Tyr Ala Met Pro Leu
1 5 10

<210> 762

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 762

Ser Asn Met Gln Pro Tyr Gln Arg Leu Ser
1 5 10

<210> 763

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 763

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Val Gly Leu Pro Ala Ala Glu
1 5 10 15

Thr Ala Cys Asn
20

<210> 764

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 764

Thr	Phe	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Met	Thr	Ile	Thr	Gly
1				5				10				15			

Lys	Val	Thr	Met
			20

<210> 765

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 765

Thr	Phe	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Ser	His	Xaa	Xaa	Val	Pro	Xaa
1				5				10					15		

Gly	Phe	Pro	Leu
			20

<210> 766

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 766

Thr	Phe	Val	Tyr	Trp	Gln	Pro	Tyr	Tyr	Gly	Asn	Pro	Gln	Trp	Ala	Ile
1				5				10				15			

His	Val	Arg	His
			20

<210> 767
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 767
Thr Phe Val Tyr Trp Gln Pro Tyr Val Leu Leu Glu Leu Pro Glu Gly
1 5 10 15

Ala Val Arg Ala
20

<210> 768
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 768
Thr Phe Val Tyr Trp Gln Pro Tyr Val Asp Tyr Val Trp Pro Ile Pro
1 5 10 15

Ile Ala Gln Val
20

<210> 769
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 769
Gly Trp Tyr Gln Pro Tyr Val Asp Gly Trp Arg

1

5

10

<210> 770

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 770

Arg Trp Glu Gln Pro Tyr Val Lys Asp Gly Trp Ser

1

5

10

<210> 771

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 771

Glu Trp Tyr Gln Pro Tyr Ala Leu Gly Trp Ala Arg

1

5

10

<210> 772

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 772

Gly Trp Trp Gln Pro Tyr Ala Arg Gly Leu

1

5

10

<210> 773
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 773
Leu Phe Glu Gln Pro Tyr Ala Lys Ala Leu Gly Leu
1 5 10

<210> 774
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 774
Gly Trp Glu Gln Pro Tyr Ala Arg Gly Leu Ala Gly
1 5 10

<210> 775
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 775
Ala Trp Val Gln Pro Tyr Ala Thr Pro Leu Asp Glu
1 5 10

<210> 776
<211> 12

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 776

Met Trp Tyr Gln Pro Tyr Ser Ser Gln Pro Ala Glu
1 5 10

<210> 777

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 777

Gly Trp Thr Gln Pro Tyr Ser Gln Gln Gly Glu Val
1 5 10

<210> 778

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 778

Asp Trp Phe Gln Pro Tyr Ser Ile Gln Ser Asp Glu
1 5 10

<210> 779

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 779

Pro Trp Ile Gln Pro Tyr Ala Arg Gly Phe Gly
1 5 10

<210> 780

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 780

Arg Pro Leu Tyr Trp Gln Pro Tyr Ser Val Gln Val
1 5 10

<210> 781

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 781

Thr Leu Ile Tyr Trp Gln Pro Tyr Ser Val Gln Ile
1 5 10

<210> 782

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 782

Arg Phe Asp Tyr Trp Gln Pro Tyr Ser Asp Gln Thr

1

5

10

<210> 783

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 783

Trp His Gln Phe Val Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 784

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 784

Glu Trp Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr Leu Leu

1

5

10

15

Arg

<210> 785

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 785

Trp Glu Gln Asn Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Phe Ala
1 5 10 15

Asp

<210> 786

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 786

Ser Asp Val Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Glu Met
1 5 10 15

<210> 787

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 787

Tyr Tyr Asp Gly Val Tyr Trp Gln Pro Tyr Ser Val Gln Val Met Pro
1 5 10 15

Ala

<210> 788

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 788

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 789

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 789

Gln Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 790

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 790

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 791

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 791

Arg Ser Leu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 792

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 792

Thr Ile Ile Trp Glu Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 793

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 793

Trp Glu Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 794

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 794

Ser Tyr Asp Trp Glu Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 795

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 795

Ser Arg Ile Trp Cys Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 796

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 796

Glu Ile Met Phe Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 797

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 797

Asp Tyr Val Trp Gln Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 798
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 798
Met Asp Leu Leu Val Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 799
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 799
Gly Ser Lys Val Ile Leu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 800
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 800
Arg Gln Gly Ala Asn Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 801
<211> 15

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 801

Gly	Gly	Gly	Asp	Glu	Pro	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 802

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 802

Ser	Gln	Leu	Glu	Arg	Thr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 803

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 803

Glu	Thr	Trp	Val	Arg	Glu	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 804

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 804

Lys Lys Gly Ser Thr Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 805

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 805

Leu Gln Ala Arg Met Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 806

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 806

Glu Pro Arg Ser Gln Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 807

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 807

Val Lys Gln Lys Trp Arg Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 808

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 808

Leu Arg Arg His Asp Val Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 809

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 809

Arg Ser Thr Ala Ser Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 810

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 810

Glu Ser Lys Glu Asp Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu

1

5

10

15

<210> 811

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 811

Glu Gly Ser Arg Glu Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 812

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 812

Glu Gly Ser Arg Glu Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 813

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 813

Val Ile Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 814
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 814
Val Trp Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 815
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 815
Ala Ser Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 816
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 816
Phe Tyr Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 817
<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 817

Glu Gly Trp Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 818

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 818

Trp Gly Glu Trp Leu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 819

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 819

Asp Tyr Val Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 820

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 820

Ala His Thr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 821

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 821

Phe Ile Glu Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 822

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 822

Trp Leu Ala Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 823

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 823

Val Met Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 824

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 824

Glu Arg Met Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 825

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 825

Asn Xaa Xaa Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 826

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 826

Trp Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu

1

5

10

<210> 827

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 827

Thr Leu Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 828

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 828

Val Trp Arg Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 829

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 829

Leu Leu Trp Thr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 830
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 830
Ser Arg Ile Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 831
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 831
Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 832
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 832
Trp Gly Tyr Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 833
<211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 833
Thr Ser Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 834
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 834
Val His Pro Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 835
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 835
Glu His Ser Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 836
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 836

Xaa Xaa Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 837

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 837

Ala Gln Leu His Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 838

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 838

Trp Ala Asn Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 839

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 839

Ser Arg Leu Tyr Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 840

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 840

Gly Val Thr Phe Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 841

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 841

Ser Ile Val Trp Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 842

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 842

Ser Arg Asp Leu Val Gln Pro Tyr Ala Leu Pro Leu

1 5 10

<210> 843
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 843
His Trp Gly His Val Tyr Trp Gln Pro Tyr Ser Val Gln Asp Asp Leu
1 5 10 15

Gly

<210> 844
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 844
Ser Trp His Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val Pro
1 5 10 15

Glu

<210> 845
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 845

Trp Arg Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Pro Glu Ser
1 5 10 15

Ala

<210> 846

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 846

Thr Trp Asp Ala Val Tyr Trp Gln Pro Tyr Ser Val Gln Lys Trp Leu
1 5 10 15

Asp

<210> 847

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 847

Thr Pro Pro Trp Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Asp
1 5 10 15

Pro

<210> 848

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 848

Tyr	Trp	Ser	Ser	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Ser	Val	His
1				5				10					15		

Ser

<210> 849

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 849

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Gly	Leu
1				5				10	

<210> 850

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 850

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10	

<210> 851

<211> 10

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 851

Glu Trp Ile Gln Pro Tyr Ala Thr Gly Leu
1 5 10

<210> 852

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 852

Asn Trp Glu Gln Pro Tyr Ala Lys Pro Leu
1 5 10

<210> 853

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 853

Ala Phe Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 854

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 854

Phe Leu Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 855

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 855

Val Cys Lys Gln Pro Tyr Leu Glu Trp Cys
1 5 10

<210> 856

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 856

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 857

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 857

Gln Gly Trp Leu Thr Trp Gln Asp Ser Val Asp Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 858

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 858

Phe Ser Glu Ala Gly Tyr Thr Trp Pro Glu Asn Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 859

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 859

Thr Glu Ser Pro Gly Gly Leu Asp Trp Ala Lys Ile Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 860
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 860
Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 861
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 861
Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 862
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 862
Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro

1

5

10

15

Tyr Ala Leu Pro Leu
20

<210> 863

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 863

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 864

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 864

Ser Trp Ser Glu Ala Phe Glu Gln Pro Arg Asn Leu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 865

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 865

Gln Tyr Ala Glu Pro Ser Ala Leu Asn Asp Trp Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 866

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 866

Asn Gly Asp Trp Ala Thr Ala Asp Trp Ser Asn Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 867

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 867

Thr His Asp Glu His Ile Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 868

<211> 21

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 868

Met	Leu	Glu	Lys	Thr	Tyr	Thr	Thr	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro
1				5				10						15	

Tyr Ala Leu Pro Leu
20

<210> 869

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 869

Trp	Ser	Asp	Pro	Leu	Thr	Arg	Asp	Ala	Asp	Leu	Tyr	Trp	Gln	Pro	Tyr
1				5				10						15	

Ala Leu Pro Leu
20

<210> 870

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 870

Ser	Asp	Ala	Phe	Thr	Thr	Gln	Asp	Ser	Gln	Ala	Met	Tyr	Trp	Gln	Pro
1				5				10						15	

Tyr Ala Leu Pro Leu

<210> 871
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 871

Gly Asp Asp Ala Ala Trp Arg Thr Asp Ser Leu Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 872
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 872

Ala Ile Ile Arg Gln Leu Tyr Arg Trp Ser Glu Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 873
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 873

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 874

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 874

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 875

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 875

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 876

<211> 21

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 876

Gln Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 877

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 877

Glu Asn Pro Phe Thr Trp Gln Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 878

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 878

Val Thr Pro Phe Thr Trp Glu Asp Ser Asn Val Phe Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu

<210> 879
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 879

Gln Ile Pro Phe Thr Trp Glu Gln Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 880
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 880

Gln Ala Pro Leu Thr Trp Gln Glu Ser Ala Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 881
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<400> 881

Glu Pro Thr Phe Thr Trp Glu Glu Ser Lys Ala Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 882

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 882

Thr Thr Thr Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 883

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 883

Glu Ser Pro Leu Thr Trp Glu Glu Ser Ser Ala Leu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 884

<211> 21

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 884

Glu	Thr	Pro	Leu	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 885

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 885

Glu	Ala	Thr	Phe	Thr	Trp	Ala	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 886

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 886

Glu	Ala	Leu	Phe	Thr	Trp	Lys	Glu	Ser	Thr	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
-----	-----	-----	-----	-----

<210> 887

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 887

Ser Thr Pro Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 888

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 888

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 889

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 889

Lys Ala Pro Phe Thr Trp Glu Glu Ser Gln Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 890

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 890

Ser Thr Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 891

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 891

Asp Ser Thr Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 892

<211> 21

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 892

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 893

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 893

Gln Thr Ala Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 894

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 894

Glu Thr Leu Phe Thr Trp Glu Glu Ser Asn Ala Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu

<210> 895

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 895

Val	Ser	Ser	Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5				10					15		

Tyr	Ala	Leu	Pro	Leu
		20		

<210> 896

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 896

Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5		

<210> 897

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is a phosphotyrosyl residue

<220>

<223> At position 2, Xaa is a 1-naphthylalanyl residue

<220>

<223> At position 6, Xaa is an azetidine residue

<400> 897

Xaa Xaa Pro Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 898

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 898

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 899

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 899

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 900

<211> 15

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 900

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 901

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 901

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 902

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 902

Glu	Thr	Pro	Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr Ala Leu Pro Leu

<210> 903

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 13, Xaa is an azetidine residue

<400> 903

Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu
1				5					10					15	

Pro Leu

<210> 904

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 904

Ala	Asp	Val	Leu	Tyr	Trp	Gln	Pro	Tyr	Ala	Pro	Val	Thr	Leu	Trp	Val
1				5					10					15	

<210> 905

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 905

Gly Asp Val Ala Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Thr Ser
1 5 10 15

Leu

<210> 906

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 906

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
1 5 10 15

Gly Leu

<210> 907

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 4, Xaa is prolyl or an azetidine
residue

<220>

<223> At position 6, Xaa is S, A, V or L

<400> 907

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 908

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is Y, W or F

<220>

<223> At position 4, Xaa is prolyl or an azetidine
residue

<220>

<223> At position 6, Xaa is S, A, V or L

<400> 908

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa

1

5

<210> 909

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is Y, W or F

<220>

<223> At position 2, Xaa is E, F, V, W or Y

<220>

<223> At position 4, Xaa is prolyl or an azetidine
residue

<220>

<223> At position 6, Xaa is S, A, V or L

<220>

<223> At position 7, Xaa is M, F, V, R, Q, K, T, S, D,
L, I or E

<220>

<223> At position 8, Xaa is E, L, W, V, H, I, G, A, D,
L, Y, N, Q or P

<400> 909

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 910

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is V, L, I, E, P, G, Y, M, T or
D

<220>

<223> At position 2, Xaa is Y, W or F

<220>

<223> At position 3, Xaa is E, F, V, W or Y

<220>

<223> At position 5, Xaa is prolyl or an azetidine
residue

<220>

<223> At position 7, Xaa is S, A, V or L

<220>

<223> At position 8, Xaa is M, F, V, R, Q, K, T, S, D,
L, I or E

<220>

<223> At position 9, Xaa is E, L, W, V, H, I, G, A, D,
L, Y, N, Q or P

<400> 910

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa

1

5

<210> 911

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 911

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu

1

5

10

15

<210> 912

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 912

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu

1

5

10

15

<210> 913

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 913

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 914

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 914

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 915

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 915

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 916

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 916

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu

1

5

10

15

<210> 917

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is A, D, E, F, G, K, Q, S, T, V
or Y

<220>

<223> At position 2, Xaa is A, D, G, I, N, P, S, T, V or
W

<220>

<223> At position 3, Xaa is A, D, G, L, N, P, S, T, W or
Y

<220>

<223> At position 4, Xaa is A, D, E, F, L, N, R, V or Y

<220>

<223> At position 5, Xaa is A, D, E, Q, R, S or T

<220>

<223> At position 6, Xaa is H, I, L, P, S, T or W

<220>

<223> At position 7, Xaa is A, E, F, K, N, Q, R, S or Y

<220>

<223> At position 8, Xaa is D, E, F, Q, R, T or W

<220>

<223> At position 9, Xaa is A, D, P, S, T or W

<220>

<223> At position 10, Xaa is A, D, G, K, N, Q, S or T

<220>

<223> At position 11, Xaa is A, E, L, P, S, T, V or Y

<220>

<223> At position 12, Xaa is V, L, I, E, P, G, Y, M, T
or D

<220>

<223> At position 13, Xaa is Y, W or F

<220>

<223> At position 14, Xaa is E, F, V, W or Y

<220>

<223> At position 16, Xaa is P or an azetidine residue

<220>

<223> At position 18, Xaa is S, A, V or L

<220>

<223> At position 19, Xaa is M, F, V, R, Q, K, T, S, D,
L, I or E

<220>

<223> At position 20, Xaa is Q or P

<400> 917

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa
1 5 10 15

Tyr Xaa Xaa Xaa Leu
20

<210> 918

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 918

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 919

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 919

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
1 5 10 15

Gly Leu

<210> 920

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 920

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 921

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 921

Glu	Asn	Thr	Tyr	Ser	Pro	Asn	Trp	Ala	Asp	Ser	Met	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
		20		

<210> 922

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 922

Ser	Val	Gly	Glu	Asp	His	Asn	Phe	Trp	Thr	Ser	Glu	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
		20		

<210> 923

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 923

Asp	Gly	Tyr	Asp	Arg	Trp	Arg	Gln	Ser	Gly	Glu	Arg	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
		20		

<210> 924
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 924
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 925
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 925
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Asn His
1 5 10

<210> 926
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 926
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Asn His
1 5 10

<210> 927
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 927
Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Asn His
1 5 10

<210> 928
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 928
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 929
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 929

Ala Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 930

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 930

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 931

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 931

Phe Glu Ala Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 932

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 932

Phe	Glu	Trp	Ala	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 933

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 933

Phe	Glu	Trp	Thr	Ala	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 934

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 934

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 935
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 935
Phe Glu Trp Thr Pro Gly Ala Trp Gln Xaa Tyr
1 5 10

<210> 936
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 936
Phe Glu Trp Thr Pro Gly Tyr Ala Gln Xaa Tyr
1 5 10

<210> 937
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 937

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Ala

1

5

10

<210> 938

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 938

Phe Glu Trp Thr Gly Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 939

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 939

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 940

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 940

Phe	Glu	Trp	Thr	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5				10	

<210> 941

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa is a pipecolic acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 941

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 942

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, Xaa is an aminoisobutyric acid
residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 942

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr

1

5

10

<210> 943

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 6, Xaa is a sarcosine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 943

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr

1

5

10

<210> 944

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa is a sarcosine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 944

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 945

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 945

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr

1

5

10

<210> 946

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 946

Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr

1

5

10

<210> 947

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 947

Phe	Glu	Trp	Thr	Val	Pro	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 948

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is acetylated phe

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 948

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 949

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa is acetylated phe

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 949

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 950

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=1-naphthylalanine

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 950

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 951

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 951

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 952

<211> 11

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 952

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 953

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 953

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 954

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 954

Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr

1

5

10

<210> 955

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 955

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr

1

5

10

<210> 956

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=naphthylalanine

<400> 956

Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met

1

5

10

<210> 957

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=naphthylalanine

<400> 957

Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr

1

5

10

<210> 958

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=naphthylalanine

<400> 958

Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser

1

5

10

<210> 959

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=naphthylalanine

<400> 959

Asn Met Val Tyr Xaa Gln Pro Tyr Ser Ile Gln Thr

1

5

10

<210> 960

<211> 9

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 960
Val Tyr Trp Gln Pro Tyr Ser Val Gln
1 5

<210> 961
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 3, Xaa=naphthylalanine

<400> 961
Val Tyr Xaa Gln Pro Tyr Ser Val Gln
1 5

<210> 962
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 7, Xaa is an azetidine residue

<400> 962
Thr Phe Val Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 963
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, Xaa =p-benzoyl-L-phenylalanine

<400> 963
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 964
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, Xaa=p-benzoyl-L-phenylalanine

<400> 964
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 965
<211> 11

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 8, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 965
Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 966
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 8, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 966
Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 967
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 7, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 967
Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10

<210> 968
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 7, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 968
Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10

<210> 969
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 3, Xaa=p-benzoyl-L-phenylalanine

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 969

Phe	Glu	Xaa	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 970

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 3, Xaa=p-benzoyl-L-phenylalanine

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 970

Phe	Glu	Xaa	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 971

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=p-benzoyl-L-phenylalanine

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 971

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 972

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated
p-benzoyl-L-phenylalanine

<220>

<223> At position 10, Xaa is an azetidine residue

<400> 972

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 973

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 973

Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln
1				5				

<210> 974

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 974

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 975

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 5, Xaa=naphthylalanine

<400> 975

Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 976

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 976

Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 977

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 977

Arg	Leu	Val	Trp	Phe	Gln	Pro	Tyr	Ser	Val	Gln	Arg
1				5					10		

<210> 978

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 978

Arg	Leu	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Ile	Gln	Arg
1				5					10		

<210> 979

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=D or Y

<220>

<223> At position 3, Xaa=D or S

<220>

<223> At position 4, Xaa=S, T or A

<220>

<223> At position 5, Xaa=S or W

<220>

<223> At position 6, Xaa=S or Y

<220>

<223> At position 7, Xaa=D, Q, E or V

<220>

<223> At position 8, Xaa=N, S, K, H or W

<220>

<223> At position 9, Xaa=F or L

<220>

<223> At position 10, Xaa=D, N, S or L

<220>

<223> At position 11, Xaa=L, I, Q, M or A

<400> 979

Xaa	Asn	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa
1				5						10

<210> 980

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 980

Asp	Asn	Ser	Ser	Trp	Tyr	Asp	Ser	Phe	Leu	Leu
1				5						10

<210> 981

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 981

Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala
1 5 10

<210> 982

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 982

Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu
1 5 10

<210> 983

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 983

Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp
1 5 10 15

Cys

<210> 984

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 984

Thr	Ser	Glu	Tyr	Asp	Asn	Thr	Thr	Trp	Tyr	Glu	Lys	Phe	Leu	Ala	Ser
1					5				10					15	

Gln

<210> 985

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 985

Ser	Gln	Ile	Pro	Asp	Asn	Thr	Ala	Trp	Tyr	Gln	Ser	Phe	Leu	Leu	His
1					5				10					15	

Gly

<210> 986

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 986

Ser	Pro	Phe	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Thr
1					5				10					15	

Tyr

<210> 987

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 987

Glu	Gln	Ile	Tyr	Asp	Asn	Thr	Ala	Trp	Tyr	Asp	His	Phe	Leu	Leu	Ser
1					5				10					15	

Tyr

<210> 988

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 988

Thr	Pro	Phe	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Thr
1					5				10					15	

Tyr

<210> 989

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 989

Thr	Tyr	Thr	Tyr	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Arg	Phe	Leu	Met	Ser
1				5					10					15	

Tyr

<210> 990

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 990

Thr	Met	Thr	Gln	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Ser
1				5					10					15	

Tyr

<210> 991

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 991

Thr	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Ala	Asn	Leu	Val	Gln	Thr	Tyr	Pro
1				5					10					15	

Gln

<210> 992

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 992

Thr	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Arg	Phe	Leu	Ala	Gln	Tyr	Pro
1				5				10						15	

Asp

<210> 993

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 993

His	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Thr	Tyr	Thr
1				5				10						15	

Pro

<210> 994

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 994

Ser	Gln	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Ser	Tyr	Lys
1				5				10						15	

Ala

<210> 995
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 995
Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn
1 5 10 15

Ala

<210> 996
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 996
Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn
1 5 10 15

Thr

<210> 997
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 997

Thr	Ile	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Asn	Phe	Leu	Leu	Asn	His	Asn
1				5				10					15		

Leu

<210> 998

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 998

His	Tyr	Asp	Asn	Thr	Ala	Trp	Tyr	Glu	Arg	Phe	Leu	Gln	Gln	Gly	Trp
1				5				10						15	

His

<210> 999

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 999

Glu	Thr	Pro	Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5				10					15		

Tyr Ala Leu Pro Leu
20

<210> 1000

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1000

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1001

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1001

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1002

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=phosphotyrosine

<220>

<223> At position 2, Xaa=naphthylalanine

<220>

<223> At position 3, Xaa=phosphotyrosine

<220>

<223> At position 5, Xaa is an azetidine residue

<400> 1002

Xaa	Xaa	Xaa	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 1003

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1003

Thr	Ala	Asn	Val	Ser	Ser	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 1004

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1004

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 1005

<211> 19
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1005

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu	Ser
1				5				10					15		

Asp Asn His

<210> 1006

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1006

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 1007

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1007

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1008

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1008

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1009

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1009

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1010

<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1010

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1011

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1011

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1012

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1012

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr

1

5

10

<210> 1013

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1013

Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr

1

5

10

<210> 1014

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1014

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 1015

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1015

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 1016

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 10, Xaa=azetidine

<400> 1016

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 1017

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<400> 1017

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 1018

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1018

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 1019

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
 PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1019

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1020

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 10, Xaa=azetidine

<400> 1020

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1021

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa=azetidine

<400> 1021

Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1022

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa=azetidine

<400> 1022

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1023

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>

<223> At position 1, Xaa=acetylated phe

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa=azetidine

<400> 1023

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1024

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1024

Gly	Gly	Leu	Tyr	Leu	Cys	Arg	Phe	Gly	Pro	Val	Thr	Trp	Asp	Cys	Gly
1				5					10					15	

Tyr Lys Gly Gly
20

<210> 1025

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1025

Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu	Thr	Trp	Val	Cys	Lys
1				5					10					15	

Pro Gln Gly Gly
20

<210> 1026

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO-MIMETIC
PEPTIDE

<400> 1026

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Leu Gly Gly
20

<210> 1027

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1027

Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
1 5 10

<210> 1028

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1028

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 1029

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1029

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly Gly
20

<210> 1030

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1030

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 1031

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1031

Cys Asn Gly Arg Cys
1 5

<210> 1032

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO MIMETIC

<400> 1032

Cys Asp Cys Arg Gly Asp Cys Phe Cys

1

5

<210> 1033

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1033

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly

1

5

10

15

Gly Gly Gly Phe

20

<210> 1034

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1034

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys

1

5

10

15

Pro Gln Gly Gly Gly Gly Gly Gly Phe

20

25

<210> 1035

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1035

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 1036

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1036

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 1037

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1037

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 1038

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1038

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys

1

5

10

15

Arg Pro Ser Pro Lys Ala

20

<210> 1039

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1039

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys

1

5

10

<210> 1040

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1040

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys

1

5

10

<210> 1041

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1041

Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 1042

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1042

Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly
1 5 10 15

Pro Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40

<210> 1043

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1043

Asp Leu Xaa Xaa Leu
1 5

<210> 1044

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1044

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu
1 5 10

<210> 1045

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF ANTAGONIST

<400> 1045

Phe Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser
1 5 10 15

Leu Gly His Arg Pro
20

<210> 1046

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF ANTAGONIST

<400> 1046

Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly
1 5 10 15

Gly Gly Gly Gly Phe
20

<210> 1047

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

<400> 1047

Phe Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1048

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

<400> 1048

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly
1 5 10 15

Gly Gly Gly Gly Phe
20

<210> 1049

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST

<400> 1049

Phe Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met
1 5 10 15

Trp Glu Trp Glu Cys Phe Glu Arg Leu
20 25

<210> 1050

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST

<400> 1050

Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu	Cys	Phe
1				5					10					15	

Glu	Arg	Leu	Gly	Gly	Gly	Gly	Gly	Phe
			20				25	

<210> 1051

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MMP INHIBITOR

<400> 1051

Phe	Gly	Gly	Gly	Gly	Gly	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu	Cys
1					5				10					15	

<210> 1052

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MMP INHIBITOR

<400> 1052

Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu	Cys	Gly	Gly	Gly	Gly	Gly	Phe
1					5					10				15	

<210> 1053

<211> 10

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1053

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr
1 5 10

<210> 1054

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1054

Arg Thr Asp Leu Asp Ser Leu Arg Thr
1 5

<210> 1055

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TNF-ALPHA
INHIBITOR

<220>

<221> CDS

<222> (4)..(747)

<400> 1055

cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
1 5 10 15

ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

20

25

30

ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 35 40 45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 50 55 60

gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 65 70 75

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 80 85 90 95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336
 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 100 105 110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384
 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 115 120 125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432
 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 130 135 140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480
 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 145 150 155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528
 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 160 165 170 175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576
 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 180 185 190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624
 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 195 200 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672
 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

210 215 220 720
 ctg tct ccg ggt aaa ggt gga ggt ggt ggt gac ttc ctg ccg cac tac
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr
 225 230 235

aaa aac acc tct ctg ggt cac cgt ccg taatggatcc 757
 Lys Asn Thr Ser Leu Gly His Arg Pro
 240 245

<210> 1056

<211> 248

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TNF-ALPHA
 INHIBITOR

<400> 1056

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220
 Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys
 225 230 235 240
 Asn Thr Ser Leu Gly His Arg Pro
 245

<210> 1057

<211> 761

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ALPH
INHIBITOR Fc

<220>

<221> CDS

<222> (4)..(747)

<400> 1057

cat atg gac ttc ctg ccg cac tac aaa aac acc tct ctg ggt cac cgt 48
 Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg
 1 5 10 15

ccg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
 Pro Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
 20 25 30

gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144
 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 35 40 45

ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192

Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	
		50					55					60				
gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	240
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	
	65					70					75					
gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	288
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	
	80					85				90					95	
cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	336
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	
				100					105					110		
cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	384
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	
			115					120					125			
gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	432
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	
		130					135					140				
ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	480
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	
		145				150					155					
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	528
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	
	160				165					170					175	
agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	576
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	
			180					185						190		
tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	624
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	
			195					200					205			
tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	672
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	
		210					215					220				
ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	720
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	
		225				230					235					
aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc	gcgg						761

Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245

<210> 1058

<211> 248

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:TNF-ALPH
INHIBITOR Fc

<400> 1058

Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro
1 5 10 15

Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
20 25 30

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
35 40 45

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
50 55 60

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
 245

<210> 1059

<211> 763

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc IL-1
 ANTAGONIST

<220>

<221> CDS

<222> (4)..(747)

<400> 1059

cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48
 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 1 5 10 15

ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96
 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 20 25 30

ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 35 40 45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 50 55 60

gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 65 70 75

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 80 85 90 95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336
 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 100 105 110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384
 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 115 120 125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432
 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 130 135 140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480
 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 145 150 155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528
 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 160 165 170 175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576
 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 180 185 190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624
 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 195 200 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672
 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 210 215 220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt ttc gaa tgg acc ccg ggt 720
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly
 225 230 235

tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag 763
 Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 240 245

<210> 1060

<211> 248

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc IL-1

ANTAGONIST

<400> 1060

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr

225

230

235

240

Trp Gln Pro Tyr Ala Leu Pro Leu

245

<210> 1061

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

Fc

<220>

<221> CDS

<222> (4)..(747)

<400> 1061

cat atg ttc gaa tgg acc ccg ggt tac tgg cag ccg tac gct ctg ccg 48

Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro

1 5 10 15

ctg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96

Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro

20 25 30

gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys

35 40 45

ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val

50 55 60

gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr

65 70 75

gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

80 85 90 95

cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His

100 105 110

cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 384
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
115 120 125

gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 432
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
130 135 140

ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 480
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
145 150 155

acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 528
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
160 165 170 175

agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 576
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
180 185 190

tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 624
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
195 200 205

tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 672
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
210 215 220

ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 720
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
225 230 235

aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 757
Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245

<210> 1062

<211> 248

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

Fc

<400> 1062

Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 20 25 30

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 35 40 45

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 50 55 60

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
 245

<210> 1063
 <211> 773
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Fc-VEGF
 ANTAGONIST

<220>
 <221> CDS
 <222> (4)..(759)

<400> 1063

cat atg gac aaa act cac aca tgt cca ccg tgc cca gca cct gaa ctc	48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu	
1 5 10 15	
ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc	96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr	
20 25 30	
ctc atg atc tcc ccg acc cct gag gtc aca tgc gtg gtg gtg gac gtg	144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val	
35 40 45	
agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg	192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val	
50 55 60	
gag gtg cat aat gcc aag aca aag ccg ccg gag gag cag tac aac agc	240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser	
65 70 75	
acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg	288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu	
80 85 90 95	
aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc	336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala	
100 105 110	
ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca	384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro	
115 120 125	
cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag aac cag	432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln	

130	135	140	
gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc			480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala			
145	150	155	
gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg			528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr			
160	165	170	175
cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc			576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu			
	180	185	190
acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc			624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser			
	195	200	205
gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc			672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser			
	210	215	220
ctg tct ccg ggt aaa ggt ggt ggt ggt ggt gtt gaa ccg aac tgt gac			720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp			
	225	230	235
atc cat gtt atg tgg gaa tgg gaa tgt ttt gaa cgt ctg taactcgagg			769
Ile His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu			
240	245	250	
atcc			773

<210> 1064

<211> 252

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST

<400> 1064

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
1					5				10					15	

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
				20				25					30		

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

35

40

45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile
225 230 235 240

His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
245 250

<210> 1065

<211> 773

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST
Fc

<220>

<221> CDS

<222> (4)..(759)

<400> 1065

cat	atg	gtt	gaa	ccg	aac	tgt	gac	atc	cat	gtt	atg	tgg	gaa	tgg	gaa	48
Met	Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu		
1				5					10					15		

tgt	ttt	gaa	cgt	ctg	ggt	ggt	ggt	ggt	ggt	gac	aaa	act	cac	aca	tgt	96
Cys	Phe	Glu	Arg	Leu	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	
				20					25					30		

cca	ccg	tgc	cca	gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	144
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	
			35					40					45			

ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	192
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	
		50					55					60				

gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	240
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	
	65					70					75					

ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	288
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	
	80				85					90					95	

ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	336
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	
				100					105					110		

acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	384
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	
			115				120						125			

gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	432
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	
		130				135						140				

gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	480
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	
	145				150					155						

cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa 528
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 160 165 170 175

ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag 576
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 180 185 190

ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc 624
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 195 200 205

tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag 672
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 210 215 220

cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac 720
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 225 230 235

cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa taactcgagg 769
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 240 245 250

atcc 773

<210> 1066

<211> 252

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:VEGF ANTAGONIST
 Fc

<400> 1066

Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys
 1 5 10 15

Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro
 20 25 30

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
 35 40 45

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 50 55 60

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
65 70 75 80

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
85 90 95

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
100 105 110

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
115 120 125

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
130 135 140

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
145 150 155 160

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
165 170 175

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
180 185 190

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
195 200 205

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
210 215 220

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
225 230 235 240

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 1067

<211> 748

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-MMP
INHIBITOR

<220>

<221> CDS
 <222> (4)..(732)

<400> 1067

cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc	48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu	
1 5 10 15	
ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc	96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr	
20 25 30	
ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg	144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val	
35 40 45	
agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg	192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val	
50 55 60	
gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc	240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser	
65 70 75	
acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg	288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu	
80 85 90 95	
aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc	336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala	
100 105 110	
ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca	384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro	
115 120 125	
cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag	432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln	
130 135 140	
gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc	480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala	
145 150 155	
gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg	528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr	
160 165 170 175	

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576
 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 180 185 190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624
 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 195 200 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672
 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 210 215 220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt tgc acc acc cac tgg ggt 720
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly
 225 230 235

ttc acc ctg tgc taatggatcc ctcgag 748
 Phe Thr Leu Cys
 240

<210> 1068

<211> 243

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-MMP
 INHIBITOR

<400> 1068

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

100	105	110
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln		
115	120	125
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val		
130	135	140
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val		
145	150	155 160
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
165	170	175
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr		
180	185	190
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val		
195	200	205
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
210	215	220
Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe		
225	230	235 240
Thr Leu Cys		

<210> 1069

<211> 763

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MMP INHIBITOR

Fc

<220>

<221> CDS

<222> (4)..(753)

<400> 1069

cat atg tgc acc acc cac tgg ggt ttc acc ctg tgc ggt gga ggc ggt	48
Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly	
1 5 10 15	

ggg gac aaa ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct	96
Gly Asp Lys Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro	
20 25 30	
tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc	144
Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro	
35 40 45	
cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca	192
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr	
50 55 60	
tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac	240
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn	
65 70 75	
tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg	288
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg	
80 85 90 95	
gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc	336
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val	
100 105 110	
ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc	384
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser	
115 120 125	
aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa	432
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys	
130 135 140	
ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat	480
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp	
145 150 155	
gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc	528
Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe	
160 165 170 175	
tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag	576
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu	
180 185 190	
aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc	624
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe	
195 200 205	

ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg 672
Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
210 215 220

aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac 720
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
225 230 235

acg cag aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 763
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245 250

<210> 1070

<211> 250

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:MMP INHIBITOR
Fc

<400> 1070

Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly
1 5 10 15

Asp Lys Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys
20 25 30

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
35 40 45

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
50 55 60

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
65 70 75 80

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
85 90 95

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
100 105 110

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
115 120 125

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
130 135 140

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
145 150 155 160

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
165 170 175

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
180 185 190

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
195 200 205

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
210 215 220

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
225 230 235 240

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 1071

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1071

Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
1 5 10

<210> 1072

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1072

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys

1

5

10

<210> 1073

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1073

Cys Leu Ser Gly Ser Leu Ser Cys

1

5

<210> 1074

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1074

Asn Gly Arg Ala His Ala

1

5

<210> 1075

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<220>

<221> CDS

<222> (10)..(189)

<400> 1075

Cys Asn Gly Arg Cys

1

5

<210> 1076

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1076

Cys Asp Cys Arg Gly Asp Cys Phe Cys

1

5

<210> 1077

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1077

Cys Gly Ser Leu Val Arg Cys

1

5

<210> 1078

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1078

Arg Thr Asp Leu Asp Ser Leu Arg

1

5

<210> 1079

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN
BINDING PEPTIDE

<400> 1079

Gly Asp Leu Asp Leu Leu Lys Leu Arg Leu Thr Leu
1 5 10

<210> 1080

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 1080

Gly Asp Leu His Ser Leu Arg Gln Leu Leu Ser Arg
1 5 10

<210> 1081

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 1081

Arg Asp Asp Leu His Met Leu Arg Leu Gln Leu Trp
1 5 10

<210> 1082
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 1082
Ser Ser Asp Leu His Ala Leu Lys Lys Arg Tyr Gly
1 5 10

<210> 1083
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 1083
Arg Gly Asp Leu Lys Gln Leu Ser Glu Leu Thr Trp
1 5 10

<210> 1084
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 1084
Arg Gly Asp Leu Ala Ala Leu Ser Ala Pro Pro Val
1 5 10

<210> 1085
<211> 15

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ANTAGONIST
PEPTIDE

<400> 1085

Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro
1 5 10 15

<210> 1086

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1086

Gly Glu Arg Trp Cys Phe Asp Gly Pro Leu Thr Trp Val Cys Gly Glu
1 5 10 15

Glu Ser

<210> 1087

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1087

Arg Gly Trp Val Glu Ile Cys Val Ala Asp Asp Asn Gly Met Cys Val
1 5 10 15

Thr Glu Ala Gln
20

<210> 1088
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1088
Gly Trp Asp Glu Cys Asp Val Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Ala Gly Val

<210> 1089
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1089
Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1090
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1090
Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1091
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1091
Gly Gly Asn Glu Cys Asp Ile Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu

<210> 1092
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST
PEPTIDE

<400> 1092
Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

<210> 1093
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1093
Cys Leu Arg Ser Gly Xaa Gly Cys
1 5

<210> 1094
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1094
Cys Xaa Xaa His Trp Gly Phe Xaa Xaa Cys
1 5 10

<210> 1095
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1095
Cys Xaa Pro Xaa Cys
1 5

<210> 1096
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1096
Cys Arg Arg His Trp Gly Phe Glu Phe Cys
1 5 10

<210> 1097
<211> 10

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1097

Ser Thr Thr His Trp Gly Phe Thr Leu Ser
1 5 10

<210> 1098

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MMP INHIBITOR
PEPTIDE

<400> 1098

Cys Ser Leu His Trp Gly Phe Trp Trp Cys
1 5 10

<210> 1099

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CARBOHYDRATE
(GD1 ALPHA) MIMETIC PEPTIDE

<400> 1099

Trp His Trp Arg His Arg Ile Pro Leu Gln Leu Ala Ala Gly Arg
1 5 10 15

<210> 1100

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PEPTIDE

<400> 1100

Leu Lys Thr Pro Arg Val
1 5

<210> 1101

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PEPTIDE

<400> 1101

Asn Thr Leu Lys Thr Pro Arg Val
1 5

<210> 1102

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PROTEIN

<400> 1102

Asn Thr Leu Lys Thr Pro Arg Val Gly Gly Cys
1 5 10

<210> 1103

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PROTEIN

<400> 1103

Lys Asp Lys Ala Thr Phe

1

5

<210> 1104

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-1 GP1AB
BINDING PROTEIN

<400> 1104

Lys Asp Lys Ala Thr Phe Gly Cys His Asp

1

5

10

<210> 1105

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PEPTIDE

<400> 1105

Lys Asp Lys Ala Thr Phe Gly Cys His Asp Gly Cys

1

5

10

<210> 1106

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:BETA-2 GP1AB
BINDING PROTEIN

<400> 1106

Thr Leu Arg Val Tyr Lys

1

5

<210> 1107

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: BETA-2 GP1AB
BINDING PROTEIN

<400> 1107

Ala Thr Leu Arg Val Tyr Lys Gly Gly

1

5

<210> 1108

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: BETA-2 GP1AB
BINDING PROTEIN

<400> 1108

Cys Ala Thr Leu Arg Val Tyr Lys Gly Gly

1

5

10

<210> 1109

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: MEMBRANE
TRANSPORTING PEPTIDE

<400> 1109

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu

1

5

10

<210> 1110

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MEMBRANE
TRANSPORTING PEPTIDE

<400> 1110

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly

1

5

10

<210> 1111

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MEMBRANE
TRANSPORTING PEPTIDE

<400> 1111

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu

1

5

10

15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu

20

25

<210> 1112

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:FC PCR PRIMER

<400> 1112

aacataagta cctgtaggat cg

22

<210> 1113

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<220>

<221> CDS

<222> (1)..(126)

<400> 1113

ccg cgg atc cat tac gga cgg tga ccc aga gag gtg ttt ttg tag tgc 48
Pro Arg Ile His Tyr Gly Arg Pro Arg Glu Val Phe Leu Cys
1 5 10 15

ggc agg aag tca cca cca cct cca cct tta ccc 81
Gly Arg Lys Ser Pro Pro Pro Pro Pro Leu Pro
20 25

<210> 1114

<211> 7

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<400> 1114

Pro Arg Ile His Tyr Gly Arg
1 5

<210> 1115

<211> 6

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<400> 1115

Pro Arg Glu Val Phe Leu
1 5

<210> 1116

<211> 12

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-TNF ALPHA
PCR PRIMER

<400> 1116

Cys Gly Arg Lys Ser Pro Pro Pro Pro Pro Leu Pro
1 5 10

<210> 1117

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TNF-ALPHA
INHIBITOR-Fc PCR PRIMER

<400> 1117

gaataacata tggacttcct gccgcactac aaaaacacct ctctgggtca ccgtccgggt 60
ggaggcggtg gggacaaaac t 81

<210> 1118

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PCR PRIMER

<400> 1118

ccgcg gatcc attacagcgg cagagcgtac ggctgccagt aaccgggggt ccattcgaaa 60
ccaccacctc cacctttacc c 81

<210> 1119

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST
-Fc PCR PRIMER

<400> 1119

gaataacata tggtcgaatg gaccccggt tactggcagc cgtacgctct gccgctgggt 60
ggaggcgggtg gggacaaaac t 81

<210> 1120

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST OLIGONUCLEOTIDE

<400> 1120

gttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg 57

<210> 1121

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST OLIGONUCLEOTIDE

<400> 1121

cagacgttca aaacattccc attcccacat aacatggatg tcacagttcg gttcaac 57

<210> 1122

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST PCR TEMPLATE

<400> 1122

gttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg 57

<210> 1123

<211> 48

<212> DNA

<213> Artificial Sequence

Description of Artificial Sequence:Fc PRIMER

> 1123

gattct agaaggagga ataacatatg gacaaaactc acacatgt

48

<210> 1124

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PRIMER

<400> 1124

gtcacagttc ggttcaacac caccaccacc acctttaccc ggagacaggg a

51

<210> 1125

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST PCR PRIMER

<400> 1125

tccctgtctc cgggtaaagg tgggtggtggt ggtggtgaac cgaactgtga catc

54

<210> 1126

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST-Fc PCR PRIMER

<400> 1126

ccgcggatcc tcgagttaca gacgttcaaa acattccca

39

<210> 1127

<211> 48

<212> DNA

Official Sequence

Description of Artificial Sequence:Fc-VEGF
ANTAGONIST-Fc PCR PRIMER

<210> 1127

atttgattct agaaggagga ataacatatg gttgaaccga actgtgac

48

<210> 1128

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-VEGF
ANTAGONIST-Fc PCR PRIMER

<400> 1128

acatgtgtga gttttgtcac caccaccacc acccagacgt tcaaaacatt c

51

<210> 1129

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-PCR PRIMER

<400> 1129

gaatgttttg aacgtctggg tgggtggtggt ggtgacaaaa ctcacacatg t

51

<210> 1130

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc PCR PRIMER

<400> 1130

ccgcgatcc tcgagttatt tacccggaga cagggagag

39

<210> 1131

Sequence:Fc-MMP

ttgggtgg tgcaaccacc acctccacct 60
66

Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-MMP
INHIBITOR-Fc PCR PRIMER

<400> 1132

gaataacata tgtgcaccac ccactggggt ttcgt gcggtggagg cggtggggac 60
aaa 63

<210> 1133

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-MMP

<400> 1133

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala
20